

From the Department of Oncology-Pathology
Cancer Center Karolinska
Karolinska Institutet, Stockholm, Sweden

**The role of the tumor suppressor gene, FBW7, and mechanisms
of its inactivation in cancer**

Shahab Akhoondi



**Karolinska
Institutet**

Stockholm 2011

Published papers were reproduced with permission from publishers when so required.
Published and printed by Karolinska University Press
Box 200, SE-171 77 Stockholm, Sweden
© Shahab Akhoondi 2011
ISBN: 978-91-7457-349-7

**To my beloved Shirin and Atrin
To my parents**

ABSTRACT

The F-box protein FBW7 is a tumor suppressor and SCF ubiquitin ligase targeting several key oncoproteins for proteasomal degradation. In this thesis we addressed whether the *FBW7* gene is inactivated by mutations in various human tumor types and explored alternative mechanism(s) for the inactivation of *FBW7*. We also explored how inactivation of FBW7 relates to substrate degradation (including cyclin E, Notch1 and c-Myc) and its potential prognostic significance. Furthermore, we have investigated novel regulatory mechanism(s) for *FBW7* expression and activity.

Our results demonstrate that *FBW7* is a general TSG, which is frequently inactivated by mutations (with an average mutation frequency of 6%) in various malignancies. Heterozygous missense mutations altering specific arginines residues required for efficient substrate interaction are the most frequent mutations in FBW7. Our functional analysis indicates that heterozygous mutations might act in a dominant-negative manner. The highest mutation frequency was observed in cholangiocarcinomas and pediatric T-cell acute lymphocytic leukemias (T-ALL) (35 and 31 %, respectively). We also found that *FBW7* gene mutation is an infrequent event in several malignancies, including breast cancer and pediatric B-ALL. This finding prompted us to investigate whether alternative mechanism for regulation and inactivation of *FBW7* occurs in cancer, including promoter hypermethylation and miRNA induced repression. Our results demonstrate that both the 5'-UTR and the 3'-UTR of *FBW7* is epigenetically regulated. The promoter of *FBW7-beta* is frequently hypermethylated in primary breast tumors and its inactivation is associated with improved survival in certain patient subgroups. Similarly, mutational inactivation of *FBW7* and/or *NOTCH1* in T-ALL is also associated with increased overall survival. Analyses focusing on the 3'UTR of *FBW7* revealed that FBW7 expression is regulated by miR-27a, a putative oncogenic miRNA. miR-27a was identified as a critical repressor of FBW7 expression during cell cycle progression with potential consequences for FBW7-mediated turnover of cyclin E. These results indicate that miR-27a serves an important cell cycle regulatory function by repressing FBW7 and at specific cell cycle stages, but releasing it from repression during the G1 to S-phase transition.

In summary, our findings demonstrate that *FBW7* is inactivated by several different

mechanisms, including mutation, deletion, promoter methylation and possibly miRNA-induced repression of gene expression. Our pre-clinical analysis further suggests that inactivation of *FBW7* in certain malignancies might be associated with improved survival, thus implicating *FBW7* as a potential prognostic predictor in the some cancers.

LIST OF PUBLICATIONS

This thesis is based on the following papers, which will be referred to in the text by their roman numerals:

Paper I:

Malyukova A, Dohda T, von der Lehr N, **Akhoondi S**, Corcoran M, Heyman M, Spruck C, Grandér D, Lendahl U, Sangfelt O., The Tumor Suppressor Gene hCDC4 Is Frequently Mutated in Human T-Cell Acute Lymphoblastic Leukemia with Functional Consequences for Notch Signaling, *Cancer Res.* 2007 Jun 15;67(12):5611-6.

Paper II:

Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grandér D, Reed SI, Widschwendter M, Sangfelt O, Spruck C., FBW7 is a general tumor suppressor in human cancer. *Cancer Res.* 2007 Oct 1;67(19):9006-12.

Paper III:

Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grandér D, Sangfelt O., Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. *Breast Cancer Res.* 2010;12(6):R105.

Paper IV:

Lerner M^{1st}, Lundgren J^{1st}, **Akhoondi S**^{2nd}, Jahn A, Ng H. F., 2, Vrieling J, Agami R, Grandér D and Sangfelt O., miRNA-27a controls FBW7-dependent Cyclin E degradation and cell cycle progression. *Cell cycle* 2011.

Table of Contents

1	List of abbreviations.....	6
2	INTRODUCTION.....	8
2.1	Cancer.....	8
2.1.1	History of cancer.....	8
2.1.2	Development of cancer.....	8
2.1.3	Oncogenes.....	10
2.1.4	Tumor suppressor genes.....	11
2.2	Ubiquitin Proteasome System (UPS)	12
2.2.1	Background/history	12
2.2.2	E3 Ubiquitin ligases.....	13
2.2.3	SCF ubiquitin ligases and Cancer.....	14
2.3	<i>FBW7</i>	15
2.3.1	History/function.....	15
2.3.2	Gene/transcript/protein	15
2.3.3	Substrates/degrons.....	17
2.3.4	Mechanism of regulation	22
2.3.5	Mechanisms of inactivation.....	27
2.4	Targeting the UPS in cancer	32
3	Aims of this thesis	34
4	Results and discussions	35
4.1	Paper I.....	35
4.2	Paper II.....	36
4.3	Paper III	39
4.4	Paper IV.....	41
4.5	Summary	43
5	Acknowledgements	44
6	References	49

1 LIST OF ABBREVIATIONS

Ago	argonaute AMFR
APC	anaphase-promoting complex
ATM	ataxia telangiectasia mutated
ATR	ataxia telangiectasia and Rad3 related
B-ALL	B-cell Acute Lymphoblastic Leukemia
BRCA	breast cancer
bTRCP	Beta Transducin Repeat Containing Protein
Cdk	Cyclin-dependent kinase
CPD	Cdc4 phosphodegron
CRL	Cullin-RING E3 ubiquitin-Ligase
CSL	CBF1 Suppressor of Hairless-Lag1
CSN	COP9 signalosome
Cul1	cullin1
DD	dimerization domain
DNA	deoxyribonucleic acid
DUB	deubiquitylating enzyme
E6AP	E6-associated protein
ER	endoplasmic reticulum
ERK	extracellular signal-regulated kinases
Far1	fatty acyl CoA reductase 1
FBXW7	F-box and WD-40 domain protein 7
GSK	glycogen synthase kinase
hCdc4	human cell division cycle 4
HECT	homologous to the E6-AP carboxyl terminus
ICD	intracellular domain
LOH	loss of heterozygosity
LRR	Leucine rich repeat
MAM	mastermind-like
MCL1	myeloid cell leukemia sequence 1
Mdm2	mouse double minute 2
miRNA	microRNA
mRNA	messenger RNA
Myc	myelocytomatosis
NICD	Notch intracellular domain
ORC	origin of replication complex
PARP	Poly ADP-ribose polymerase

PEST	proline (P), glutamic acid (E), serine (S), and threonine (T)
PI3K	Phosphatidylinositol 3-kinases
Pop1, 2	processing of precursor 1, 2
PP2A	protein phosphatase 2 A
PTEN	phosphatase and tensin homolog
RAS	rat sarcoma viral oncogene homolog
RING	really interesting new gene
RNA	ribonucleic acid
RNAi	RNA interference
SCF	Skp1/Cul1/F-box
Ser	serine
Sic1	stoichiometric inhibitor of Cdk1-Clb
Skp1	S-phase kinase-associated protein 1
Skp2	S-phase kinase-associated protein 2
T-ALL	T-cell Acute Lymphoblastic Leukemia
TGF	transforming growth factor
Thr	threonine
TM	transmembrane
TP53	tumor protein p53
TSG	Tumor suppressor gene
Ub	ubiquitin
Ubc	ubiquitin conjugating enzyme
UBD	ubiquitin binding domain
UPS	ubiquitin proteasome system
USP28	ubiquitin specific peptidase 28
UTR	untranslated region
WNT	wingless

2 INTRODUCTION

This thesis touches upon various concepts in cell biology including tumor suppressor genes, oncogenes, gene regulatory mechanisms such as DNA methylation and microRNA expression, phosphorylation, ubiquitylation and some other aspects of processes that are dysregulated in cancer. The reason is that *FBW7*, a gene originally shown to be a tumor suppressor through its negative effect on proteins promoting proliferation, is now known to be a multifunctional gene involved in many different biological processes. Since it became apparent that *FBW7* is a master regulator of many well-known oncoproteins, it was important to determine how it may be regulated and how it is functionally inactivated in tumors. The studies in this thesis show that the *FBW7* gene is in fact inactivated via various mechanisms in different human tumors. Although it is not fully understood how *FBW7* gene inactivation contributes to cancer development and progression, it is the beginning of the way that will eventually lead to better understanding of the role of *FBW7* in tumorigenesis and treatment of cancer.

2.1 CANCER

2.1.1 History of cancer

The oldest documented case of cancer was recorded on a papyrus from ancient Egypt, in 1500 b.c. However, Hippocrates, the great Greek physician (460-370 B.C), who is referred to as the father of medicine is thought to be the first person who named "cancer". Hippocrates used the name karkinos (the Greek name for crab, in English carcinos or carcinomas) to describe a skin wound that he thought of as a particular disease. His writings contain detailed descriptions of different types of cancers involving various sites in the body [1].

2.1.2 Development of cancer

In ancient Egypt, it was believed that cancer was caused by the Gods. Hippocrates believed that an excess of black bile in any given site in the body caused cancer and it was also the general thought for the cause of cancer in the next 1400 years. Despite stunning progress in our understanding of the cells that build up the human body

during the last four decades, it is not yet possible to exactly define cancer in a way that covers all its characteristics. In the simplest version, cancer has been defined as increased proliferation and survival of cells. A normal cell knows when and to what extent to grow and divide or maybe die. Normal cells are also responsive to the negative regulatory signals that they receive from the external environment. A cancer cell however, is insensitive to these signals. Cancer cells have achieved the capacity to escape from many different kinds of controls, which have elegantly been summarized by Hanahan and Weinberg in “The Hallmarks of Cancer” [2, 3]. Today we know that the development of cancer is a multistep process, and as recently described, there are 10 hallmarks of cancer [3] that collectively describe a malignancy (Figure 1). These capabilities namely, self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death (apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis are shared by most, and perhaps all, types of human cancers. Hopefully, knowing these underlying mechanisms of tumor development will facilitate the discovery of novel treatment strategies for the clinic. Many of the anti-cancer drugs that have been generated during the last decades target one or multiple of these characteristic hallmarks.




Figure 1. Hallmarks of cancer

Globally, there are approximately 7.4 million cancer deaths annually. Cancer is a leading cause of death worldwide and it accounts for approximately 13% of deaths from all causes. Encouragingly, during recent years, cancer mortality has stabilized in

many countries. Part of this success may be attributed to the development of new cancer agents, collectively called 'targeted therapies' [4, 5].

2.1.3 Oncogenes

The discovery of the double helical DNA structure in 1953 by James Watson and Francis Crick was a revolution in biology since it explained DNA's potential for replication and information encoding [6]. Simultaneous development of techniques such as DNA hybridization suddenly enabled scientists to address many key issues in cancer biology. Although foreboded by earlier studies such as those of chromosome abnormalities, hereditary cancer and the involvement of mutagens in tumorigenesis, modern molecular biology enabled scientists to define the involvement of specific mutations in cancer development. This led to the breakthroughs in the 1970s and early 80s, when oncogenes and tumor suppressor genes were discovered. An oncogene is a gene that when mutated into an activated form has the potential to cause cancer. Oncogenes encode proteins that are involved in processes such as cell proliferation and apoptosis [7]. The products of oncogenes act at multiple levels in the cell and can be transcription factors [8], chromatin remodelers [9-11], growth factors [12], growth factor receptors [13], signal transducers [14] and apoptosis regulators [15, 16].

2.1.3.1 *Mechanisms of activation*

A proto-oncogene is a normal gene converted into an oncogene if altered and activated. The resultant protein is called oncoprotein [17, 18]. Activation mechanisms of oncogenes can be categorized into three main classes: 1) Chromosomal rearrangements, 2) Mutations and 3) Gene amplification, all of which confer a growth advantage or increased survival of cells carrying such alterations [19]. All three mechanisms cause either structural alterations or an increased, deregulated expression of the oncoprotein [7, 20]. Examples of proto-oncogenes frequently dysregulated in cancer development are RAS, WNT and MYC. The expression of oncogenes can also be dysregulated by other processes such as epi-genetic alterations as well as microRNAs (miRNAs). The latter are a newly discovered group of small regulatory RNAs, that control gene expression through either translational repression or mRNA degradation [21]. Dysregulation of such miRNAs can thus lead to the subsequent activation of the oncogene [22].

2.1.4 Tumor suppressor genes

The discovery of proto-oncogenes and oncogenes provided a powerful explanation of how the growth and proliferation of cells is positively regulated. Accepting the assumption that biological systems are balanced indicated that there could be genes that counteract proto-oncogenes and prevent cells from uncontrolled growth. It was in the 1970s and early 1980s a second, and fundamentally different type of growth regulating genes began to accumulate [23]. These genes were named "Tumor suppressor genes" (TSGs) and possess anti-proliferative properties [23]. TSGs are defined as recessive genes that must sustain mutations or deletions of both alleles in order to contribute to cancer formation. This definition was described by Knudson and it known as Knudson's 'two-hit' rule [24]. It was later shown that some TSGs are exceptions to the Knudson's 'two-hit' rule, referred to as haploinsufficient TSGs. Those genes contribute to tumor development even in the presence of one functional allele [25]. The functions of tumor-suppressor proteins are diverse but can be classified into different categories, including cell cycle regulation (e.g pRb, p27, p53), DNA damage (e.g ATM, ATR) and repair (i.e BRCA1, BRCA2), apoptosis (e.g p53, BAX), migration and invasion (e.g DLC1, PTEN), senescence (e.g p16, p19) [26-33].

2.1.4.1 Mechanisms of inactivation

Haploinsufficient TSGs may become inactivated following deletion or mutation of one single allele. However, since TSGs are often recessive, cells that contain one functional and one mutated gene (heterozygous) still behave normally. There are several mechanisms by which the normal allele may then become inactivated, which in turn can predispose a cell to cancer development. Among these mechanisms are large homozygous deletions or duplication of the mutated chromosome and complete loss of the normal counterpart, leading to so called Loss of Heterozygosity (LOH), as well as small deletions, point mutations, insertions, promoter hypermethylation and dominant negative effects [34, 35].

2.2 UBIQUITIN PROTEASOME SYSTEM (UPS)

2.2.1 Background/history

A requirement for normal cellular homeostasis [36, 37] is that proteins are continuously synthesized and degraded inside our cells. This was first postulated by Schönheimer in 1942 in his book "The dynamic State of Body Constituents [38]. Proteins that have served their functions and are no longer needed have to be removed. Additionally, misfolded or damaged proteins also need to be rapidly eliminated which could otherwise cause various kinds of problems to the cell [39]. For a long time, proteins were thought to be degraded in lysosomes [40], and it took several decades before the pioneering work by Ciechanover, Hershko and Rose resulted in the discovery of a regulated energy-dependent protein degradation process which is catalyzed by specific enzymatic activities and a small ubiquitous protein named ubiquitin (Ub) [40]. This discovery was awarded the Nobel Prize in chemistry in 2004 [41]. Ubiquitylation is the covalent attachment of ubiquitin to one or more lysine residues on a substrate protein and involves a cascade of key enzymatic activities: 1) a ubiquitin-activating enzyme (E1), that activates ubiquitin in an ATP dependent manner; 2) a ubiquitin-conjugating enzyme (E2); and 3) a ubiquitin-ligase (E3), that transfers the ubiquitin to specific lysine residues on target substrates (Figure 2). Ubiquitylated substrates are then recognized by a large multi-subunit protease complex, which is named the 26S proteasome complex [42, 43]. Thus, the UPS can be divided into two distinct steps: ubiquitylation and proteasomal degradation (Figure 2). Importantly, ubiquitin contain seven lysines, which all serve as potential acceptor sites for another ubiquitin molecule and can therefore result in different ubiquitin chains on substrates [40]. In fact, the attachment of different types of ubiquitin chains on substrates can take several forms, each with potentially different biological outcomes. For example, attachment of a single ubiquitin (monoubiquitylation) often activates transcription factors, regulates protein trafficking, or targets proteins to the secretory/endocytic pathway [44]. Attachment of a chain of lysine-48 linked ubiquitins (also called poly-ubiquitylation) usually targets the substrate to the 26S proteasome for ubiquitin-mediated proteolysis [43] (Figure 2). However, other types of polyubiquitin chains (e.g lysine-63) can exert nonproteolytic functions, including kinase and transcription factor activation and chromatin remodelling [45]. In addition, many proteins contain so-called ubiquitin-binding domains (UBDs) [46, 47] enabling an

additional level of regulation and translation of ubiquitin modifications into diverse cellular outputs, similar to protein phosphorylation. Finally, ubiquitylation is counteracted by deubiquitylating enzymes (DUBs) highlighting the reversibility of this enzymatic system [40]. Given the critical function of an intact UPS, altered degradation of cellular regulators directly contributes to the development of hallmarks of cancer.




Figure 2. Ubiquitin Proteasome System (UPS)

2.2.2 E3 Ubiquitin ligases

E3 ubiquitin ligases are responsible for facilitating the attachment of the ubiquitin molecule to a lysine residue on the target protein via isopeptide bonds and therefore act as substrate specificity factors [48]. There is a huge number of E3 ligases in the cell and can be characterized by the presence of either a HECT (Homologues to E6AP C-Terminus) domain or a RING (Really Interesting New Gene) domain [49, 50]. The HECT domain containing E3s directly transfer ubiquitin from the E3 onto the substrate, whereas the RING domain provides a docking site for the E2 enzyme, which mediate the transfer of ubiquitin to the substrate [49]. E3 ligases can also be classified into single subunit E3s (e.g. Mdm2, Cbl) and multi-subunit complexes. The multisubunit RING E3s (e.g APC and SCF) includes several hundred members and can be further subdivided into different families based on the complex composition [50]. E3 enzymes bind their cognate target substrates through various protein-protein interaction

domains (e.g WD40 repeats). However, for a substrate to be recognized by an E3 ligase it generally first has to be post-translationally modified, for example by phosphorylation or proteolytic cleavage [48]. The modified motif in the substrate has been termed degron [51]. There are many different types of degrons (e.g phosphodegron, PEST). Once modified, a degron in a substrate might be recognized by a specific E3 ligase, which forms the basis for its subsequent ubiquitylation.

2.2.3 SCF ubiquitin ligases and Cancer

An important family of multimeric E3s is known as SCF (Figure 3). SCF ligases are composed of an invariant core ligase comprised of the adaptor protein Skp1, the scaffold protein Cullin1 and the RING domain protein Rbx1 (also called Roc1 or Hrt1), which recruits the E2 enzyme Cdc34 (also known as UBCH3) and one variable component called the F-box protein. It is the F-box protein that provides substrate specificity, usually through its C-terminal protein-protein interacting domains (often containing WD 40 and LRR repeats). The F-box protein associates with the SCF core through binding to the adaptor protein Skp1, via its conserved F-box domain (Figure 3) [52, 53]. The F-box is a protein domain of approximately 40-50 amino acids in length. It was first identified in cyclin F, as its name implies [52]. In the human genome, there are about 70 genes with F-box domains, each likely targeting a unique set of substrates for degradation [54]. Notably, a majority of the F-box proteins are still completely uncharacterized [55].




Figure 3. SCF ligase

A wealth of evidence suggests that SCF ligases play important roles in the control of cell division, which is almost a hallmark itself for this category of genes [Pagano]. Not surprisingly, several F-box proteins have been directly linked to tumorigenesis [56]

through their role in the regulation of critical substrates frequently dysregulated in cancer. Skp2 (FBL1) is an oncoprotein that catalyzes the ubiquitylation of p27, a cyclin-dependent kinase (CDK) inhibitor and tumor suppressor that negatively regulates cell cycle progression. Interestingly, Skp2 also catalyzes ubiquitylation and degradation of multiple other proteins regulating cell cycle progression and tumor development (eg, p130, p21) [56, 57]. Indeed, many studies clearly show that E3 ligases and F-box proteins themselves act as critical oncoproteins or tumor suppressor proteins consistent with their role in ubiquitinating an array of substrates directly linked to the development of cancer.

2.3 FBW7

2.3.1 History/function

FBW7 (also known as *FBXW7*, *FBW7* or *hCDC4* in humans, *Cdc4* in *Saccharomyces cerevisiae*, *Sel-10* in *Caenorhabditis elegans*, or *Ago* in *Drosophila melanogaster*), is a substrate specificity factor for the SCF ubiquitin ligase SCF^{FBW7}[58]. *FBW7* was first identified in a genetic screen for cell division cycle (Cdc) mutants in *S. cerevisiae* [59] and was later implicated in the ubiquitin-dependent proteolysis of the cyclin-dependent kinase (Cdk) inhibitors Sic1 and Far1 [60], among others. In mammals, *FBW7* also regulates cell cycle progression and development through the degradation of specific transcription factors and cyclins [48, 61] (see below). Thus, *FBW7* is a master regulator of cellular proliferation with important implications for several pathways regulating differentiation and development.

2.3.2 Gene/transcript/protein

In humans, the *FBW7* gene spans over 200 kb on the long arm of chromosome 4 (4q31). It contains 13 exons and is alternatively spliced into three transcripts with unique 5'-exons termed alpha, beta and gamma [61] [62]. The 5'-exon of each transcript is linked directly linked to exon 2 and each mRNA thus share all C-terminal exons (exon 2-11) (Figure 4). Importantly, the individual 5' exons are coding and therefore generate three distinct protein isoforms that differ only at their N termini [63]. This genomic organization is highly conserved in mammals and also allows for

isoform-specific transcriptional regulation, as each *FBW7* isoform is expressed from its own promoter [63]. The FBW7 protein contains several protein-protein interaction domains (Figure 4). The F-box domain that recruits the SCF core complex through interaction with SKP1 protein [52] is localized in the N-terminal portion of the protein. The C-terminal exons in FBW7 encode eight WD40 repeats that form a barrel-shaped beta-propeller structure that is responsible for protein-protein interaction [64]. An additional domain in the N-terminus of the protein, termed the dimerization domain (DD), has been shown to mediate FBW7 dimerization [65-67]. While all FBW7 protein isoforms share the DD, F-box and WD40 domains, the alpha and gamma exons lack obvious domain structures, whereas the beta isoform encodes a putative transmembrane domain (TMD) [68-70]. The physiological significance for having three protein isoforms with exactly the same substrate-binding domain is still unclear, although the different FBW7 isoforms are differentially expressed among different tissues. Importantly, the FBW7 isoforms occupy different subcellular compartments in the cell [68]. A cis-acting signal in the 5' specific exons directs the alpha and beta isoforms to the nucleoplasm and cytoplasm, respectively [71]. In contrast, the nuclear gamma isoform also localizes to the nucleolus [68]. The beta isoform was recently reported to be localized to in the membrane of the Endoplasmic Reticulum (ER) [72], but may also localize to mitochondria (Steve Reed, personal communication).




Figure 4. The *FBW7* gene structure

2.3.3 Substrates/degrons

The interaction between FBW7 and its target substrates is dependent on a specific motif common in all substrates [73, 74]. This motif was identified through structural studies of Cdc4 in *S. cerevisiae* and a human phosphopeptide from cyclin E [74, 75] and was named the Cdc4-Phospho-Degron (CPD). Importantly, data from several substrates defined a CPD consensus sequence; Φ -X- Φ - Φ - Φ -pT/PS-P-P-X-pS/pT/E (Φ corresponding to a hydrophobic residue and X any amino acid) [76], which is found in all target proteins. Structural and mutational studies demonstrated that the major contacts between the FBW7 and its substrate(s) occurs through hydrogen bonds between a phosphorylated threonine/serine in the CPD and several arginine residues located in a binding pocket on the inner rim of the beta-propeller surface of FBW7 [69, 75]. However, the affinity for a specific substrate also seem to depend on the number of CPDs, and on the actual amino acid sequence in each respective substrate [76]. To date, FBW7 has been reported to target 20 different proteins for degradation (Table 1) and as such, FBW7 is involved in the regulation of multiple biological processes (Figure 5, 6). Importantly, the common denominator for these substrates is that they all act as critical oncoproteins. Some of these substrates are described in greater detail below.

Table 1. FBW7 substrates in mammals

Name	Degron	Protein category	Function
	θXθθθ(S/T)PXX (S/T/E)		
Cyclin E	LLTPPQSGK IPTPKEDD	Regulatory	Proliferation*
c-Myc	LTPPLSPS	Transcription factor	Proliferation*
c-Jun	GETPPLSPI	Transcription factor	Proliferation*
SREBP 1	TLTPPPSDA	Transcription factor	Metabolism
SV40 large T antigen	PPTPPPEPE	Oncoprotein	Transformation
Notch 1	FLTPSPESP	Transcription factor	Differentiation*
Presenilin 1	IYTPFTEDT	Regulatory	signaling
Cyclin E2	LLTPPQSGK IPTPKEDD	Regulatory	Cell cycle*
MCL1	GSAGASPST ADAIMSPEEE	regulatory	Apoptosis
C/EBPalpha	HPTPPPTP	Transcription factor	Differentiation
KLF5	LNTPLDLM PPSPPSSE NLTPPPSY	transcription factor	Proliferation
Aurora A	?	Kinase	Proliferation*
mTOR	LLTPSIHL	Kinase	Proliferation*
c-Myb	?	Transcription factor	Proliferation
SRC	SPMAS	Transcription factor	Proliferation
PGC1	PLTPESPN GLTPPTTP	Transcription factor	Metabolism
n-Myc	?	transcription factor	Proliferation
TGIF1	FNTPPPTP	regulatory	signaling
Ebp2 (pseudosubstrate)	?	Regulatory	Ribosome biogenesis
PKC (atypical substrate-no degradation)	?	Kinase	Signaling

θ, hydrophobic amino acid; X, any amino acid, * additional functions

2.3.3.1 Cyclin E1

Cyclin E, an activator of Cdk2, is involved in the initiation of DNA replication and other cell cycle functions [77]. Cyclin E/Cdk2 catalyzes the phosphorylation of many substrates that are involved in diverse S phase processes such as histone biosynthesis, centrosome duplication, and the licensing of origins of replication (ORC), among others [78]. In normal cells, the level of cyclin E peaks at the G1/S phase boundary and rapidly declines as cells progress into S phase. However, in many tumors cyclin E protein levels are elevated and/or dysregulated relative to cell cycle progression and these

alterations have a strong prognostic impact for poor outcome in patients with breast cancer [79, 80]. Overexpression of cyclin E has been shown cause a premature initiation of DNA synthesis [77, 81] and induce chromosome instability in cultured cells [78]. Furthermore, deregulated cyclin E expression in mice leads to tumor formation [82]. Finally, cyclin E can transform rat embryo fibroblasts together with oncogenic Ras [83], in line with its oncogenic function. The first indication for ubiquitin ligase mediated proteolysis of cyclin E was provided by reports of the Cul1 knockout mouse [84, 85]. Cul1 deficiency in mice resulted in embryonic lethality with arresting cells containing elevated levels of cyclin E [84]. In 2001, three groups including our own, independently identified the F-box protein FBW7 as a novel SCF ligase responsible for cyclin E ubiquitylation and degradation [69, 86, 87]. FBW7 was found to bind specifically to cyclin E that is phosphorylated on two CPDs, one surrounding Thr62 and one at Thr380 [88-91]. Phosphorylation of cyclin E1 is mediated by Cdk2 on residues Thr380 and Ser384 through autophosphorylation and also by glycogen synthase kinase 3 (GSK3) [89]. Interestingly, whereas FBW7-beta does not appear to be involved in cyclin E turnover, both FBW7-alpha and gamma are required for cyclin E degradation in cultured cells [91, 92]. Using in vitro and in vivo ubiquitylation assays, we found that ubiquitylation of cyclin E requires sequential function both the alpha and the gamma isoforms [91].

2.3.3.2 *Notch 1*

The *Notch1* gene is a member of the Notch family of transmembrane receptors [93]. Notch proteins have an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain. Notch proteins play a key role in a variety of developmental processes and regulate differentiation, survival, and proliferation through an evolutionarily conserved intercellular signaling pathway. Canonical Notch signaling is initiated and activated following ligand (Jagged) interaction and sequential proteolytic cleavages by ADAM metalloproteases and the gamma-secretase complex [93]. Proteolytic release of the intracellular domain of Notch (NICD) from the cell membrane results in translocation of the NICD to the nucleus where it promotes the transcriptional activation of DNA-binding transcription factor including CSL and MAM. NICD forms a trimeric complex with CSL and the co-activator MAM, which is essential for NICD-dependent transcription *in vitro* and *in vivo* [94]. The first Notch receptor gene to be identified in humans,

Notch1, was discovered through the analysis of DNA flanking the breakpoints of a recurrent t(7;9)(q34;q34.3) chromosomal translocation seen in a small subset (< 1%) of human pre-T-cell acute lymphoblastic leukemias [95]. *Notch1* is frequently mutated in T-ALL but is also deregulated in variety of other human tumors, including breast cancer and various subsets of human lymphomas [96, 97]. The first link between Notch and FBW7 came from studies demonstrating that LIN-12 (the NOTCH1 orthologue in *C. elegans*) is regulated by SEL-10 (the Cdc4 orthologue in *C. elegans*) [98, 99]. In 2001, the mouse and human homologs of FBW7 was shown to target Notch1 for ubiquitylation [100]. Interestingly, Notch1 is also controlled by several other ubiquitin ligases [99, 101-103]. The PEST domain of NICD is known to regulate protein stability and is often mutated in primary human and mouse T-ALLs [104]. Indeed, the Notch1 PEST domain contains putative CPD motifs [105]. The important function of FBW7 in Notch regulation is underscored by the fact that *FBW7* knockout mice die early during embryonic development mainly due to abnormalities in vascular development which is attributed to failure in the degradation of Notch [103, 106].

2.3.3.3 *c-Myc*

The *MYC* proto-oncogene encodes a nuclear transcription factor and regulates up to 15% of all genes [107]. Because of this, *MYC* regulates a broad spectrum of cellular functions, including cell growth, proliferation and apoptosis among others [108-110]. Loss of *Myc* results in embryonic lethality in mice and depletion of *Myc* forces cells to exit the cell cycle. Conversely, *Myc* expression stimulates progression through the cell cycle and its overexpression in cells or animals induces transformation [111, 112]. Indeed, the *MYC* gene is one of the most frequently overexpressed oncogenes and is estimated to contribute to as many as 70% of all human cancers [113-116]. Thus, a tight control of *Myc* expression and activity is essential for normal cellular homeostasis. Like cyclin E, *MYC* expression is regulated by upstream kinases such as the PI3K-AKT-GSK3b pathways, which is responsible for the rapid degradation of *Myc* by the ubiquitin-proteasome pathway. Increased stability of *Myc* is frequently observed in various human tumors and this has mainly been attributed to point mutations in the N-terminus of *Myc*, a region, which also encodes a CPD. Indeed, subsequent studies showed that *FBW7* targets *Myc* for ubiquitin-mediated proteolysis in a phosphorylation dependent manner [117-119]. The exact mechanism for *Myc*

ubiquitylation is not known. Like cyclin E, Myc degradation appears to depend on additional cofactors (see below) and both the nuclear isoforms of FBW7 [68]. Interestingly, at least five ubiquitin ligases have been implicated in Myc ubiquitylation and turnover, including three F-box proteins (Cdc4, SKP2 and bTRCP) [120].

1.3.3.4 Other substrates

As mentioned above, the list of novel FBW7-specific target substrates is rapidly expanding, as is the number of biological pathways regulated by FBW7. Figure 5 and Table 1 summarize the extensive number of substrates we know today. From this list, it is evident that FBW7 is not only responsible for the tight regulation of the cell division cycle, but also control growth, signal transduction, differentiation, survival and metabolism. Although most established substrates are nuclear proteins degraded by the nuclear isoforms of FBW7, alpha and gamma [68], it is intriguing that there are yet no defined substrates for the cytoplasmic FBW7-beta isoform [61]. Whereas knockout mice lacking FBW7 are not viable, a recent study shows that mice specifically deleted for the FBW7-beta isoform do not exhibit any apparent development defects. However, primary cultures of neurons prepared from the mutant mice are more sensitive to oxidative stress than those prepared from the wild-type mice. Conversely, overexpression of FBW7-beta renders cells resistant to the oxidative stress. These results thus suggest that FBW7-beta might contribute to the protection of cells from oxidative stress [72].




Figure 5. FBW7 substrates and regulators

2.3.4 Mechanism of regulation

2.3.4.1 Expression

As described above, FBW7 is a critical suppressor of mammalian cancerogenesis through its negative regulation of various oncoproteins (Figure 5). However, we still have very limited knowledge about the regulatory mechanisms controlling FBW7 expression and activity in cells. The fact that different isoforms possess distinct promoters suggest that each isoform is differentially regulated [58]. Indeed, each isoform specific transcript is differentially expressed in different tissues [62, 87]. FBW7-alpha is ubiquitously expressed compared to [63] FBW7-beta which is highly expressed in brain but absent in skeletal muscle and liver [121]. FBW7-gamma expression is low in most tissues but high in muscle [62]. Very little is known how isoform specific expression is regulated. The alpha promoter resides within a 2 kb CpG island, whereas the gamma and beta promoters lack obvious CpG islands. The FBW7-alpha and beta transcripts are transcriptionally induced by the p53 tumor suppressor [70, 122] in response to DNA damage. However, only the beta promoter contains a consensus p53 binding site [70]. However, we have shown by ChiP-seq analysis that p53 binds a region downstream of exon 11 (Selinova G., unpublished observations) which could promote p53-induced transcriptional activation of the

alpha isoform. Interestingly, the inflammatory response gene CCAAT/enhancer binding protein- δ , C/EBP δ , has been shown to directly inhibit expression of FBW7 during hypoxia through targeting the promoter region of FBW7-alpha [123]. Interestingly, we recently discovered that the gamma transcript is induced upon serum-withdrawal mediated myoblast differentiation of C2C12 cells (unpublished data). Furthermore, gene expression data indicate that FBW7 expression may be transcriptionally induced under low oxygen conditions. A potent epigenetic mechanism for the regulation of gene expression during normal development and cellular differentiation in higher organisms is DNA methylation [124]. We recently demonstrated that the beta promoter is hypermethylated in multiple different tumor-derived cell lines and primary breast tumors (paper III) and it is thus possible that methylation of the different FBW7 promoters determines isoform specific expression in different normal tissues. Another potential mechanism for regulation of FBW7 expression is microRNAs (miRNAs). miRNAs are short non-coding RNAs of about 21-23 nucleotides in length that regulate gene expression at the post-transcriptional level [125, 126]. Despite their recent discovery, miRNAs are now widely accepted as critical gene expression regulatory factors [125, 126]. miRNAs are expressed by RNA polymerase II as parts of longer primary transcripts or miRNA precursors termed pri-miRNAs [127, 128]. Maturation of miRNAs involves the sequential processing by protein complexes containing an RNase III enzyme Drosha and the Dicer-TRBP complex respectively [129], followed by incorporation into a complex termed RISC (RNA-induced silencing complex) [130, 131]. The degree of complementarity between microRNA and mRNA will generally dictate the outcome; perfect or near-perfect complementarity will result in cleavage of the mRNA, while imperfect complementarity will trigger translational repression [132]. The human genome contains between 400 to 1000 different miRNAs, as estimated by computational methods [133]. Approximately 50% of all genes are predicted targets of miRNAs [134]. Apparently, each miRNA targets many different genes and each 3'UTR often contains binding sites for many different miRNAs [135-137]. Because of their widespread role in regulation of gene expression, it is easy to understand that miRNAs have profound effects on tumor development. In fact, many miRNAs have been shown to act as tumor suppressors and oncogenes [22]. With this in mind, we set out to identify miRNAs that might regulate FBW7 expression. Using a combination of different screening procedures, we found that the 3'UTR of FBW7 is regulated by at

least 5 different miRNAs. Interestingly, one of these miRNAs, miR-27a, was found to regulate FBW7 expression during cell cycle progression (paper IV). In fact, this is the first demonstration that FBW7 expression is regulated during specific cell cycle phases under physiological conditions (paper IV). Interestingly, miR-223 was recently reported to regulate FBW7 expression as well [138]. Interestingly, miRNAs often act in concert with specific RNA binding proteins. It is becoming increasingly clear that miRNA function often depends on RNA binding proteins [137]. There are still no reports on the role of RNA-binding proteins regulating FBW7 expression. However, our results indicate that miR-27a-mediated repression of FBW7 is minimal at the G1/S border, without any obvious change in miR-27a expression levels. This suggests that the interaction between miR-27a and the FBW7-3'UTR is regulated by additional factors, as has been demonstrated for the cyclin-dependent kinase inhibitor p27 mRNA and the miRNAs miR-221/miR-222 which is dynamically regulated by the RNA-binding protein Pumilio-1 [139]. Future studies will reveal in greater detail how FBW7 is regulated by miR-27a during the cell cycle and whether it's regulated by specific RNA binding proteins.

1.4.1.2 Activity

FBW7 function and activity is also regulated at the post-translational level. As described above, FBW7 function as a SCF ubiquitin ligase when bound the Skp1-Cul1-Roc1 complex. Thus, the general regulation of components in the core ligase is also of importance for FBW7-specific substrate ubiquitylation. Indeed, it has been shown that SCF activity requires an active neddylation system [140]. For example, recent observations indicate that conformational changes induced by Cullin-RING E3 ubiquitin-Ligases (CRL) dimerization and by conjugation of the ubiquitin-like protein NEDD8 on the cullin subunit stimulates substrate polyubiquitination [141]. Conversely, Deneddylation, in which the COP9 signalosome (CSN) removes NEDD8 from cullins, inactivates CRLs [142]. Interestingly, it is very difficult to detect endogenous FBW7 protein expression in cells although FBW7 mRNA levels are easily detected. The reason for this is not completely understood, but could be due to miRNA-mediated translational repression, or possibly, decreased protein stability. Indeed, we, (unpublished data) and others [143] have shown that FBW7 protein is unstable and auto-ubiquitylated *in vivo*. Notably, the WD40 beta-propeller structure was recently shown to function as an ubiquitin-binding domain and ubiquitin

interaction by Cdc4 was demonstrated to promote its autoubiquitylation and turnover [144].

We have very limited knowledge of direct post-translational modifications regulating FBW7 activity. However, FBW7 is phosphorylated through ATM/ATR pathway upon induction of DNA damage [145]. Additionally, FBW7 was recently reported to be a novel substrate for PKC and mutational analysis revealed that PKC-mediated phosphorylation of the FBW7-alpha isoform at serine 10 regulate its nuclear localization [146]. There are as yet no reports for post-translational modifications of the beta and gamma isoforms.

In addition to the F-box and WD40 domains, FBW7 contains a dimerization domain (DD)(Figure 4) located immediately N-terminal to the F-box domain. The D-domain is highly conserved among different species [66, 147] and is also found in other F-box proteins. For example, human beta-TrCP1 and beta-TrCP2, form hetero- and homodimers in vivo [66, 147] and the two FBW7 homologs in fission yeast, Pop1 and Pop2, also form hetero- and homo-complexes [148]. Human FBW7 also forms homodimers and possibly heterodimers [67]. The role of dimerization of F-box proteins is not exactly understood, but has been proposed to increase the ubiquitylation efficiency of substrates with low-affinity phosphodegrons [65, 66], possibly through reducing the distance between the substrate and the SCF catalytic site. Juxtaposition of two E2 sites in proximity to the substrate may also increase reaction kinetics [66]. However, FBW7 dimerization is not an absolute requirement for cyclin E degradation [65]. Additional studies need to firmly establish how dimerization regulates substrate ubiquitylation. Moreover, SCF^{FBW7} localization and activity is also regulated by various cofactors. We, and others have previously shown that SCF^{FBW7} mediated cyclin E and Myc ubiquitylation depends on the peptidyl-prolyl cis/trans isomerase Pin1 [91, 149]. Pin1 is a multifunctional enzyme that isomerizes many proteins with S/TP motifs [150]. We showed that ubiquitylation of cyclin E requires the sequential function of FBW7-alpha and gamma isoforms [91]. Whereas FBW7-gamma polyubiquitylates cyclin E, FBW7-alpha forms a ternary complex with cyclin E and Pin1 and isomerizes the cyclin E phosphodegron. Pin1 is also required for FBW7 mediated Myc degradation, in conjunction with the protein phosphatase 2A (PP2A) [118]. Thus, PP2A is another factor regulating FBW7 activity towards specific

target substrates [118]. The functional effects of these cofactors during tumor development are complex but may be of therapeutic potential in cancer treatment [151-155]. The deubiquitylating enzyme, ubiquitin-specific protease 28 (USP28), is an example of a negative regulator of SCF^{FBW7} activity. USP28 also forms a complex with FBW7-alpha and cyclin E or c-Myc [156] in the nucleus, possibly counteracting ubiquitylation by the FBW7-alpha isoform in the nucleoplasm [156]. Interestingly, upon DNA damage induced by UV irradiation, the USP28-associated ternary complex is disassembled [157] which result in declined steady-state levels of Myc protein rapidly after exposure [156]. Degradation of Myc and cyclin E (unpublished data) by FBW7 may be compartmentalized, as both Myc and cyclin E have been shown to accumulate in the nucleolus upon proteasomal inhibition ([91], Bhaskaran et al, unpublished). Together, these data suggest that ubiquitylation of Myc and cyclin E is catalyzed by the FBW7-gamma isoform in the nucleolus [91]. At present, it is unclear whether ubiquitylation of other FBW7 substrates are also regulated in a similar compartmentalized manner. Nucleophosmin (NPM), also termed B23, is a dynamic, multifunctional protein that is tightly regulated during proliferation and it was recently shown to regulate FBW7-mediated Myc ubiquitination and transcriptional activity [158, 159]. Our own unpublished data also support a function for NPM in the regulation of cyclin E stability. Thus, it is possible that NPM may be involved in shuttling these substrates to the nucleolus. Ebp2 is another potential factor regulating the translocation of FBW7 to nucleoli by functioning as a pseudosubstrate for FBW7 [71]. Finally, FBW7-dependent substrate ubiquitylation is also dependent on upstream signaling pathways, including the PI3K/Akt/GSK3b pathway [160] and possibly Ras signaling [161].

2.3.5 Mechanisms of inactivation

2.3.5.1 Phenotypes

While FBW7 null mice die around 10.5 days post coitus due to a combination of deficiencies in hematopoietic and vascular development attributed to dysregulation of Notch1 [103], tumors with inactivation of FBW7 exhibit various functional alterations related to other FBW7 substrates. Considering the fact that FBW7 orchestrates the destruction of a number of key onco-proteins it is maybe not surprising that FBW7 function has been linked to several important processes such as proliferation, apoptosis and differentiation. Thus, FBW7 inactivation causes the undermined regulation of several specific cellular programmes associated with the major hallmarks of cancer (Figure 6).




Figure 6. A simplified overview of cellular processes regulated by FBW7

Recently *FBW7-beta* deficient mice have been generated. Interestingly, no cancer development was detected in these mice up to 1 year. Also these animals did not exhibit any apparent abnormalities in development, however longer observation will be necessary to determine whether *Fbxw7b*-deficient mice are predisposed to cancer development [72].

One obvious phenotype in cells with *FBW7* inactivation is genetic instability [162, 163]. The genetic instability phenotype might be mediated due to increased levels and dysregulated expression of a several key oncogenic *FBW7* target substrates, including *c-Myc*, cyclin E1 and *STK15/AURKA* protein [164]. During recent years there has been an effort to show which of these substrate(s) that is more likely to be responsible for the genomic instability caused by *FBW7* ablation, with ample data supporting the relevance of dysregulated cyclin E1. Overexpression of cyclin E can also recapitulate phenotypes observed in cells with inactivated or suppressed *FBW7*, and conversely, knockdown of cyclin E expression in cancer cell lines with a genomic instability phenotype reduces percentage of micronuclei formation [162]. Taken together, cyclin E1 dysregulation phenocopies several phenotypes observed upon ablation of *FBW7*[78]. The genomic instability of *FBW7*-deficient cells is at the microscopic level manifested as nuclear atypia characterized by micronuclei, lobulated or elongated nuclei, aberrant chromosomal structures at metaphase, abnormal number of centromeres and multipolar spindles [162]. Furthermore, *FBW7*-deficient tumor cells undergo extensive mitotic slippage and endoreduplication when exposed to spindle toxins such as vinblastine or taxol, which in turn render them polyploid [165].

2.3.5.2 Mutation

Early reports analyzing the *FBW7* gene sequence identified chromosomal rearrangements and mutations in the *FBW7* gene in human tumor-derived cell lines [86, 87]. Shortly thereafter, it was shown that primary endometrial tumors contain *FBW7* mutations [63]. Interestingly, *FBW7* mutation was found to correlate with cyclin E dysregulation in these tumors [63]. Mutations were subsequently identified in colon carcinomas and pancreatic cancer [63, 166, 167]. Our original discovery of *FBW7* mutations in primary endometrial adenocarcinomas was the basis for continued analysis of *FBW7* mutations in primary tumors. Mutational analysis of

FBW7 in pediatric T-ALL showed that this malignancy has a particularly high frequency of mutations (paper I). These studies were followed up with a comprehensive screen for *FBW7* mutations in 1556 primary human tumor samples from twelve different malignancies (paper II). The results from these analysis established that *FBW7* represent a general TSG in human cancers [168]. The overall mutation frequency of *FBW7* in different tumors is 6% and the highest mutation frequencies were found in tumors of the bile duct (cholangiocarcinomas, 35%), blood (T-cell acute lymphocytic leukemia, 31%), endometrium (9%), colon (9%), and stomach (6%) [168]. The most common mutations in *FBW7* are missense mutations of three arginine residues (Arg⁴⁶⁵ and Arg⁴⁷⁹) in the substrate binding pocket of *FBW7* [168, 169]. Interestingly, these mutations presumably function in a dominant-negative manner, possibly through dimerization with the functional wild-type allele. The reason why mutations frequently occur in these specific nucleotides of *FBW7* (exon 8 and exon 9) is not known, but could be due to spontaneous deamination of 5'-methylcytosine to thymine in DNA. Indeed, the cytosine corresponding to the mutation hotspot at nucleotides 1,435–1,436 (Arg⁴⁷⁹) is methylated in vivo [168]. Some discrepancies in the mutation frequencies have been reported. For example in T-ALL samples, *FBW7* has been shown to be mutated between 10 to 30 % [170-172], but all laboratories report clustering of mutations in *FBW7* binding pocket. One plausible explanation for such differences is the ethnical differences between the patients enrolled in different studies. Other factors could be differences in sample size or other types of selection biases.

Various types of single nucleotide polymorphisms (SNPs)(Synonyme, nonsynonyme and frameshift) possibly affecting *FBW7* function have been reported to occur in all three isoforms (ensembl.org).

2.3.5.3 Deletion

Deletion of the *FBW7* gene, which localizes chromosome 4q31 is a frequent event in human tumors and occurs in more than 30% of all neoplasms [173]. Several studies have reported deletion of one allele at 4q31 [173, 174]. We have also demonstrated small deletions of *FBW7* occurring in a breast cancer cell line [87]. A previous report showed that *FBW7*^{-/+} mice crossed with p53 heterozygous mice have a greater susceptibility to radiation-induced tumors [122]. Interestingly, most of these tumors retain and express the wild-type *FBW7* allele, indicating that *FBW7* might be a p53-

dependent haploinsufficient tumor suppressor gene [122]. In another study it was shown that FBW7 exhibited intestinal tumors carry heterozygous FBW7 mutations, again indicative of FBW7 being a haploinsufficient tumor suppressor gene [175]. However, in these studies, detailed analysis of FBW7 isoform specific expression was not performed.

1.5.1.4 Methylation:

Several recent reports have shown that FBW7 expression is downregulated in some tumor types, including glioblastomas [176], gastric [177] and colorectal cancer [178]. However, the mechanism for loss of expression was not clarified in these studies [179]. DNA methylation is generally defined as the addition of a methyl group to the 5 position of a cytosine base, but it can occur on adenine base as well. Methylation is epigenetically inherited from parental cells to the daughter cells upon cell division. [180]. DNA methylation is an important mechanism for the regulation of gene expression during normal development and cellular differentiation in higher organisms [124, 180]. Alterations in the methylation pattern, particularly at TSG gene loci, is also a frequent event in cancer [124]. In paper III, we report that *FBW7-beta* promoter is hypermethylated in human breast cancer and various tumor derived cell lines [121, 181]. Comparison of *FBW7-beta* promoter methylation and FBW7-beta expression demonstrated that methylation correlates with loss of expression, suggesting that promoter hypermethylation is an alternative mechanism for FBW7 gene inactivation (paper III). Taken together, these data indicate that methylation might be an important mechanism of *FBW7-beta* gene inactivation in different tumor types [121]. A recent report showed that the *FBW7-beta* promoter is also methylated in thymoma [181]. Whether the other FBW7 promoters are methylated in cancer remains to be shown, but our methylation analysis in breast cancer specimens show no evidence for hypermethylation of the alpha promoter (paper III).

1.5.1.5 microRNAs

miRNAs are now widely accepted as critical factors involved in the regulation of gene expression [125, 126]. In most instances, the microRNA will bind to sites within 3' untranslated regions (3'-UTRs) of the targets. Today, the link between microRNAs and tumorigenesis is well-established [125] and microRNAs have been found to be deleted, downregulated or overexpressed in many different tumor types and have

been demonstrated to function as both tumor suppressors or oncoproteins [22]. *FBW7* has a long and extremely well-conserved 3'-UTR with multiple putative microRNA binding sites. Thus, *FBW7* is likely to be regulated by miRNAs. The first report that *FBW7* is indeed regulated by miRNAs was just recently published [138]. The granulocyte specific miR-223 was identified as a regulator of *FBW7* using a screen for miRNAs downregulated in cyclin E^{T74A, T393A} knock-in erythroblasts (Xu *et al*, 2010). Interestingly, miR-223 is responsive to acute alterations in cyclin E regulation by *FBW7* and it was suggested that miR-223 is part of a feedback loop connecting cyclin E activity to the regulation of *FBW7* expression [138]. miR-223 is also overexpressed in several solid tumors [182] and increased expression has also been reported in T-ALL [183]. The relationship between miR-223 and *FBW7* in tumors is however not known. We recently identified miR-223 and five additional miRNAs, miR-27a/b, miR-182 and miR-363/92 as potential regulators of *FBW7* expression (paper IV). However, our data suggest that miR-27a is the most general regulatory miRNA for *FBW7*. Indeed, our data indicate that miR-27a is a physiological regulator of *FBW7* expression during cell cycle progression and that is required for tight regulation of cyclin E degradation at the G1/S border. Thus, it is possible that overexpression of miR27 may contribute to dysregulated cyclin E expression and tumor development. Our findings were also confirmed by a recent study demonstrating miR27 as critical suppressor of *FBW7* expression [184]. Interestingly, in this study, upregulation of miR-27a was shown to contribute to the malignant transformation of human bronchial epithelial cells induced by the SV40 small T antigen [184].

2.3.5.4 Viruses

Many major TSGs have been shown to be inactivated by specific tumor viruses. Simian virus 40 (SV40) is a well-characterized member of the polyomavirus family. The SV40 encodes three proteins based on alternative splicing, the large T (LT), small T (ST) and 17 kT antigens [185-187].

Interestingly, SV40 Large T Antigen can also inhibit *FBW7*-driven cyclin E turnover *in vivo* resulting in increased cyclin E associated kinase activity. LT contains a CPD, which is recognized by *FBW7* and thus alters the normal capacity of *FBW7* in targeting other substrates [187]. Thus, the binding of LT to *FBW7* occurs via a decoy phospho-epitope within the C-terminus of LT that closely mimics the consensus Cdc4 phospho-degron (CPD) found within *FBW7* substrates [187].

Human adenoviruses are a group of small DNA viruses that are capable of transforming rodent cells in culture and also induce tumors in hamsters or rats. Two viral oncogenes, termed E1A and E1B, have been identified as critical factors for adenoviral induced transformation through inactivation of the TSGs RB and p53 [188]. A recent report suggests that E1A can interfere with FBW7 function by targeting the SCF^{FBW7} complex [189]. E1A was found to directly bind to Roc1/Rbx1 and CUL1 and inhibit the ubiquitin ligase activity of core ligase, resulting in impaired degradation of several proto-oncogene products that are normally degraded by the SCF^{FBW7} ubiquitin ligase [189].

2.3.5.5 Other factors

As mentioned above, SCF^{FBW7} activity is regulated by several cofactors and most likely various post-translation modifications that could be of major importance for inactivation of FBW7 in cancer. There are contradictory results regarding the role of Pin1 in tumorigenesis [152, 154, 155] but it could potentially interfere with FBW7 function [91]. The deubiquitylating enzyme USP28 has been shown to be overexpressed in colon and breast carcinoma [156] and could possibly prevent FBW7-mediated degradation cyclin E and c-Myc [157]. Other cofactors, including NPM and Ebp2 could also in principle also interfere with FBW7 substrate degradation. Indeed, NPM is frequently mutated in AML and NPM mutations have been demonstrated to mislocalize FBW7 protein [190]. Upstream signaling cascades stimulating FBW7 substrate degradation, including the GSK3b [191] and the Ras [192] pathway, are frequently dysregulated in human tumors and may therefore be of major importance preventing FBW7 from degrading specific oncoproteins.

2.4 TARGETING THE UPS IN CANCER

During recent years there have been major efforts to develop drugs targeting the UPS system in cancer cells [193]. The fact that the UPS regulates important tumor suppressors first raised the possibility that inhibition of the 26S proteasome might be beneficial in the treatment of cancer patients. However, targeting the 26S proteasome will also stabilize critical oncoproteins and it is not possible to predict whether the inhibition of the 26S proteasome will necessarily be beneficial. Nevertheless, Bortezomib (Velcade), a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome, was approved by the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma in 2004. Today, Bortezomib is used for the treatment of hematologic malignancies as well as solid tumors such as breast cancer and several clinical trials, utilizing Bortezomib in combination with other drugs are ongoing [190, 194-198]. However, more specific drugs are warranted. The E3 ligases are particularly attractive drug targets since they are responsible for the recognition and ubiquitylation of specific substrates. In addition, it is now clear that one single E3 ligase often targets multiple proteins for degradation. For example, the F-box protein oncoprotein Skp2, targets several important tumor suppressor proteins, including the CDK inhibitor p27 [199], which is frequently downregulated in many different tumors [200]. As outlined in this thesis, FBW7 also targets multiple proteins for degradation, all being critical oncoproteins. Furthermore, we recently showed that the small-molecule inhibitor, RITA, reactivates p53-induced FBW7 expression resulting in proteasomal degradation of several FBW7 target substrates [201]. Interestingly, our results indicate that FBW7 inactivation is associated with a favorable prognosis and increased survival (paper I, III, IV). The reason for this is presently unclear. However, exciting results demonstrating synthetic lethal interaction for certain genes, including ATM and p53 [202], and PARP and BRCA1 [203], may hint that FBW7 could also be synthetic lethal with specific genes. A recent study identified a compound that act as an inhibitor of SCF^{Cdc4} in yeast [204], demonstrating that this type of E3 ligase can in principle be inactivated by small-molecules. The future will clarify whether targeting FBW7 or its cofactors with drugs can be used in the treatment of patients with cancer.

3 AIMS OF THIS THESIS

The overall aim of this thesis was to explore the mechanisms by which FBW7 is inactivated in human cancers.

Specific aims:

- To investigate if FBW7 is mutated in pediatric B- and T-ALLs (paper I)
- To elucidate if FBW7 is a general tumor suppressor gene (Paper II)
- To explore if methylation is an alternative mechanism for inactivation of FBW7 expression in cancer (Paper III)
- To investigate if FBW7 is regulated by microRNAs (Paper IV)

4 RESULTS AND DISCUSSIONS

4.1 PAPER I

The Tumor Suppressor Gene hCDC4 Is Frequently Mutated in Human T-Cell Acute Lymphoblastic Leukemia with Functional Consequences for Notch Signaling.

At the beginning of this project, very little was known about whether FBW7 is mutationally inactivated in specific tumors. The findings that Notch1 is a novel FBW7 target substrate that is frequently targeted by gain of function mutations in T-ALL prompted us to investigate the possibility that FBW7 inactivation contributes to the development of pediatric leukemia.

We used SSCP (Single Strand Conformation Polymorphism assay) and sequence analysis to screen the entire coding region of *FBW7* and *Notch1* in 26 pediatric leukemic T- and 20 B-lineage ALL samples.

Interestingly, *FBW7* mutations were found in 8 of the 26 T-ALL specimens (31%) while no mutations were observed in leukemic cells from B-ALL patients. All mutations were missense mutations and the majority (88%) led to amino acid changes of Arginine 465 and Arginine 479, which are located within the substrate recognition site of FBW7. FBW7 mutations were absent in cells from matching nonmalignant leukocytes obtained from the same patients, indicating that these mutations were of somatic origin. Additionally, similar mutations were also found in several cell lines derived from various hematological malignancies, particularly of T-cell origin. No hCDC4 mutations were identified in any other leukemia or lymphoma cell lines analyzed, with the exception of the multiple myeloma cell line U266-1984, which harbored an Arginine 505 missense mutation. Notably, one leukemic sample was found to harbor a Notch1 missense mutation resulting in a threonine to methionine substitution at position 2,484 in the PEST domain of Notch1. The amino acids surrounding threonine 2484 in Notch1 resembles a consensus CPD motif, suggesting that this mutation might prevent its recognition by FBW7. However, several truncating PEST domain mutations occur downstream of this motif, which suggests that multiple CPD motifs may be present in Notch1 ICD and regulate its degradation [74].

In line with Notch1 being a FBW7 substrate, Notch1 protein analysis in T-ALL cell lines showed that cell lines with hCDC4 mutations had elevated levels and increased stability of Notch1 ICD, as compared with T-ALL cell lines where hCDC4 was not mutated. Furthermore, we found that wild-type (wt), but not mutant *FBW7-alpha/gamma* isoforms, could restore ubiquitylation of Notch1 in vivo, and that expression of wt-FBW7 (but not mutant FBW7) decreased Notch1 signaling.

Importantly, our data indicated that mutations in *Notch1 and/or FBW7* associates with a favorable long-term survival in children with T-ALL. This was the first report showing that FBW7 is mutated in pediatric T-ALL with functional consequences for Notch signaling. Previous studies from our group and others reported *FBW7* mutations in endometrial adenocarcinomas [63] and colon [167]. However, the mutation frequency in those solid tumors were lower (16% and 6%).

In summary, previous work had shown that Notch1 signaling is commonly upregulated in T-ALL. In this paper, we show that the negative regulator of Notch1, *FBW7*, is frequently mutated in T-ALL. This data also extends previous findings, and suggests that mutation in hCDC4 and/or NOTCH1 is associated with improved overall survival of children with T-ALL. The finding that two genes in the same pathway, NOTCH1 and FBW7, are both frequently mutated in children with T-ALL is remarkable and emphasizes the importance of this pathway in T-ALL development and possibly therapeutic intervention and refined risk stratification.

4.2 PAPER II

FBXW7/hCDC4 Is a General Tumor Suppressor in Human Cancer.

Inspired by the frequent mutations of FBW7 found in T-ALL, we wondered whether FBW7 is inactivated in other tumors as well, and if it could represent a general tumor suppressor gene in human malignancy.

A total of 534 primary tumor specimens from 12 different tumor types were included in this study and analyzed by SSCP (Single Strand Conformation Polymorphism assay)

and sequence analysis for mutations in all 13 exons, including sequences unique to the three isoforms, alpha, beta and gamma. We next compiled these results with pre-existing *FBW7* mutation data (a total of 1556 samples). Table 2 summarizes of the mutational analysis.

Table 2. Summary of *FBW7* mutational analysis

<i>Mutation type</i>	Percentage (%)	Additional information
Single amino acid change	96	(missense 74%, nonsense 26%)
Deletion and insertion	4	
Isoform specific mutations	6	
<i>Average mutation frequency</i>	6	<i>87 mutations out of 1556</i>
<i>Tumor types</i>		
Breast	0.8	
Bladder	0	
Cholangiocarcinoma	35	
Colon	9.5	
Endometrium	9	
esophagus	0	
Leukemia	31	T-ALL (31%), B-ALL (0), B-CLL (0), HCL (0), AML (0)
Liver	0	
Lung	3	NSCLC
Melanoma	0	
Bone	0	
Ovarian	0	
Prostate	1	A proline insertion in Alpha isoform
Pancreas	9	Only one study (1 mutation in 11 patients)
Stomach	15	

Abbreviations: B-CLL, B-cell chronic lymphocytic leukemia; B-ALL, B-cell acute lymphocytic leukemia; T-ALL, T-cell acute lymphocytic leukemia; HCL, hairy cell leukemia; NSCLC, non-small cell lung carcinoma.

Analysis of this large set of tumors confirmed and extended previous analysis. The majority of the mutations cluster in the critical arginines previously shown to be responsible for the interaction between *FBW7* and the phosphodegron of specific

substrates. Thus, mutations clustered at hotspot codons, encoding several arginine residues in the FBW7 WD40 repeats.

Investigation of the mutational hotspots showed that all are centered on CG dinucleotides, which are potential sites of DNA methylation and a source for mutations due to deamination of 5'-methylcytosine to thymidine in DNA.

Indeed, we could show that the cytosine at the hotspot codon 479 was methylated in all tumors analyzed. Thus, these mutations seem to correspond to methylated CG sites, which could explain the high frequency of such missense mutations.

To examine the consequence on substrate binding of the hotspot mutations, we analyzed their ability to bind one of the FBW7 key substrates, cyclin E. None of the mutants could bind cyclin E (in contrast to wt-FBW7) and this was not due to mislocalization of the FBW7 mutants.

Regarding the fact that majority of the mutations were heterozygous raised the possibility that these mutations might interfere with the protein expressed from the normal wild-type allele of *FBW7*. Indeed, when co-expressed, mutant-FBW7 resulted in a marked accumulation of cyclin E1 despite expression of wt-FBW7. These results are well in agreement with findings that FBW7 forms dimers *in vivo* and it is therefore possible that mutations in only one allele of *FBW7* is enough to compromise substrate degradation through a dominant-negative function.

Interestingly, our analysis also demonstrates that mutations occur in the unique isoform specific 5'-exons. The functional consequences of mutations in specific isoforms are not fully understood, but could for example lead to mislocalization of a specific isoform. Indeed, we could show that a proline insertion in a prostate cancer specimen that resided at the amino acid 16 of the FBW7-alpha isoform mislocalized FBW7-alpha to the cytoplasm and thus preventing it from interacting with cyclin E1. Additionally, one FBW7-alpha specific mutation has been shown to disrupt the interaction between FBW7 and its cofactor Pin1 [91]. Together, these data suggest that FBW7 isoforms are non-redundant.

In summary, this paper is the first comprehensive screen for mutations in *FBW7* in diverse human tumor types. The results demonstrate an overall average mutation frequency of 6% and potential dominant negative hotspot mutations clustering in exon8 and exon9 of *FBW7*.

4.3 PAPER III

Inactivation of *FBXW7/hCDC4-b* expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.

During the work with paper II, it became obvious that many tumors lack mutations in *FBW7*, although several of these tumors are known to have increased levels of specific *FBW7* target substrates. For example, elevated cyclin E levels are frequently observed in breast tumors, but *FBW7* is not found to be mutated in this malignancy. In addition, our preliminary analysis of *FBW7* expression in both primary tumors and derived cell lines indicated that the expression of *FBW7* varied significantly between and within different tumor types.

In the present study, we therefore examined the possibility that *FBW7* expression is downregulated through promoter specific hypermethylation, as an alternative epigenetic mechanism for inactivation of *FBW7* in cancer.

The *FBW7*-beta isoform was chosen for further analysis; since it showed the most variable expression pattern among a panel of different tumor-derived and immortalized cell lines. Interestingly, using bisulphate sequencing and methylation-sensitive restriction digestion analysis, we found that the *FBW7-beta* promoter is heavily methylated in multiple tumor cell lines. Expression analysis showed that hypermethylation of the beta- promoter associates with a decreased expression of the *FBW7-beta* mRNA. In order to establish a direct link between methylation and expression we treated cells with a methylated beta- promoter with the demethylating agent, 5-AZA cytidine (AZA). Bisulphite sequencing and expression analysis revealed that expression of *FBW7-beta* was restored and its promoter was demethylated upon 5-AZA treatment. Additional investigations, including luciferase reporter assays with

an in vitro methylated promoter, also support the conclusion that *FBW7-beta* expression is regulated by promoter specific methylation.

We next asked whether *FBW7-beta* methylation also occurs in primary tumors. A total of 161 breast cancer specimens, from two independent cohorts (Austria and Sweden), were subject to methylation and expression analysis. The methylation status in each tumor sample was defined by restriction digestion test using McrBc enzyme. This method uses methylation-sensitive restriction McrBc enzyme, to cleave DNA at specific methylated-cytosine residues followed by amplification of the resultant products. The PCR amplification bands were then subject to quantification using Image J software. *FBW7* isoform specific mRNA expression levels were analyzed by real time PCR (RT-PCR). Importantly promoter methylation was absent in normal breast tissue (and in other noncancerous tissue DNA extracted from paraffin-embedded breast cancer specimens).

A total of 71 out of 139 (51%) patient samples showed significant methylation of the beta promoter as defined by McrBc digestion, compared to its undigested control. Thus, as in tumor cell lines, there was a significant inverse correlation between promoter methylation and *FBXW7/hCDC4beta* expression in primary breast cancer specimens.

Interestingly, comparison of the *FBW7-beta* promoter methylation status of the individual samples with various clinicopathological factors, demonstrated that methylation associates with high-grade tumors ($p= 0.017$) and possibly estrogen receptor-negative tumors ($p=0.08$), thus tumors usually associated with an adverse prognosis in breast cancer. Remarkably, methylation of the *FBW7beta* promoter was anyhow found to be associated with a decreased risk of death ((cohort 1 hazard ratio 0.53 (0.23 to 1.23) and cohort 2 (HR) 0.50 (95% CI 0.23 to 1.08)) in both cohorts despite the correlation between methylation and high-grade tumors. When methylation was compared to overall survival in defined subgroups of the breast cancer, including patients with p53 mutation or lymph node negative tumors, patients with a methylated beta promoter had an improved overall survival.

In summary, this study is the first report of *FBW7* promoter hypermethylation and loss of expression in primary tumors. Our data support promoter methylation as an

alternative mechanism for FBW7 inactivation in cancer. The frequency of methylation is high (>50%) and links loss of FBW7-beta expression to high-grade tumors. However, patients with a methylated beta promoter still appear to have a decreased risk of death. The reason why methylation is linked to improved survival is presently unclear, but could possibly relate to increased sensitivity of methylated tumors to certain therapeutic drugs. This possibility, and its potential as a novel biomarker are areas that need further investigation.

4.4 PAPER IV

miRNA-27a controls FBW7/hCDC4-dependent Cyclin E degradation and cell cycle progression.

In paper III, we showed that FBW7 expression is regulated by methylation of specific CpG dinucleotides in the 5' UTR of FBW7. Another mechanism for regulation of gene expression is through miRNA binding to specific seed sequences in the 3'UTR of genes [205]. Interestingly, the FBW7 3'UTR is long and extremely conserved and contains a large number of putative miRNA binding sites. The aim of this study was therefore to investigate if FBW7 expression is regulated by miRNAs.

An initial observation that FBW7 protein expression is elevated in cells with a targeted deletion of the miRNA-processing enzyme, Dicer, suggested that FBW7 3'UTR is indeed controlled by miRNAs .

In order to identify relevant candidate microRNAs that potentially repress FBW7 expression, we employed a combination of computational predictions, luciferase reporter assays, miRNA library screens and expression profiling analysis. Luciferase reporter assays was initially utilized to identify cell lines where FBW7 is repressed by endogenous miRNA expression. miRNA expression profiling in combination with computer-based prediction of candidate miRNAs and a miRNA library screen identified miR-27a as a strong candidate for the repressive effect in the model cell lines utilized.

Further validation analysis confirmed that miR-27a is a negative regulator of FBW7 expression. Mutation of two putative miR-27a binding sites located in the 3'UTR

region of FBW7 completely abolished the suppressive effect of miR-27a and inhibition of miR-27a by antagonists increased FBW7 expression. In addition, miR-27a overexpression reduced endogenous FBW7 protein levels in a dose-dependent manner. Together, these results confirm a direct function for miR-27a in the negative regulation of FBW7.

To evaluate the functional effect of miR-27a on FBW7, we performed several experiments to test if miR-27a specifically regulates the stability and ubiquitylation of FBW7 target substrates. miR-27a overexpression resulted in increased steady-state levels of cyclin E and myc which was due to an increased stability and decreased ubiquitylation of these proteins.

To date, we have very limited knowledge on if and how FBW7 is regulated during the cell cycle. To directly test if miR-27a regulates FBW7 during the cell cycle, we analyzed *FBW7*-3'UTR reporter activity (by comparing the wild-type 3'UTR with the miR-27a-mutated 3'UTR) in U2OS cells progressing from mitosis towards S-phase. Importantly, miR-27a was found to potently repress FBW7 at the G2/M and early G1 phases, but not at the G1/S transition. First of all, these results provide evidence that miR-27a regulates FBW7 in a physiological setting, during cell cycle progression. Second, the lack of repression at the G1 to S-border, indicates that miR-27a may release FBW7 from repression at this critical cell cycle stage, just prior to FBW7-mediated cyclin E degradation at early S-phase. Third, overexpression of miR-27a significantly elevated cyclin E levels in later cell cycle stages and increased the number of cells in S-phase. In line with these results, miR27 overexpression induced DNA double-strand breaks (DSBs), as analyzed by gamma-H2AX foci formation, a phenotype directly related to dysregulation of cyclin E protein. Importantly, our results demonstrate that these effects are likely to be FBW7-dependent, as cyclin E degradation and gamma-H2AX foci formation was rescued by expression of FBW7 lacking the 3'UTR.


The fact that miR-27a is a negative regulator of FBW7 and is overexpressed in tumors, suggests that it may act as a novel oncogene. Interestingly, analysis of miR27a expression in pediatric B-ALL, a tumor type in which *FBW7* is not mutated, showed that miR27 is significantly overexpressed in several B-ALL subtypes compared to normal bone marrow cells and CD34+ B cells. Additionally, in hyperdiploid pre-B-ALL, a

significant inverse correlation between miR-27a expression and FBW7 mRNA expression was evident.

In summary, this study has unraveled a novel role for miR-27a, a ubiquitously expressed and putatively oncogenic miRNA, in the fine-tuned regulation of FBW7 function during the cell cycle. Our results also demonstrate that miR-27a is overexpressed in pediatric B-ALL, and show that in hyperdiploid B-ALL cases, increased levels of miR-27a are generally correlated with low levels of FBW7.

4.5 SUMMARY

Summary



5 ACKNOWLEDGEMENTS

I would like to express all my regards and gratitude to all people who supported and cared for me during these years. I have had the chance to have many wonderful people around me whose support made all this possible. In particular I would like to thank:

Olle Sangfelt, my supervisor and dear friend. I never forget when I was waiting to meet you for the first time at the CCK entrance. I was expecting an old man with glasses in suit and tie but when you eventually came in jeans and a t-shirt with all those muscles, I believed it's possible to have a brilliant mind and a perfect body at the same time. First of all, I am extremely grateful that you allowed me to start my PhD and thereafter, I would have not been able to proceed and accomplish without your encouraging attitude by all means (Albeit, except those times that you had to renew your grants and fill out applications. Nag nag nag). It's a great and invaluable feeling when you are sure that your supervisor thoughtfully follows your progress and indeed you gave me this feeling. You were always attentive to my concerns and behaved in a way that I could improve myself without feeling bad. I believe that you need to pretend or at least try sometimes not to be so nice.

Dan Grander, my supervisor and dear friend. I would like to deeply thank you for letting me start my PhD in your group and for being one of the persons that made all this happen. Unfortunately, I cannot brag about having you as a great friend and support, since undoubtedly so many people share this with me even beyond CCK borders. When I talked to you through the phone for the first time, I was 5000 kilometers away but you perfectly managed to make me feel in about 5000 milliseconds that I can conveniently and freely talk to you. When I joined the group you gave me confidence and you listened to all my "sincere scientific ambitions" such as my goal to change the history of science and amazingly you didn't laugh at me (or maybe you did later!). Your comments even in the gym are of great value and finally, during all these years I couldn't really figure out how you follow after lunch discussions when you take nice short naps and suddenly wake up and give a comment directly to the point!

Babak Noori Nayer, you were my first supervisor and definitely the one who made this long journey to begin. You allowed me to join your lab and start being involved in the endless world of research. I deeply appreciate your sincere intentions to improve the research in our country. Your intelligence will make this dream come true, someday but certainly, for sure!

Alena Malyukova, you were the first postdoc who was assigned to teach me and I can imagine how tough it would have been for you to deal with a medical doctor that had no sense of molecular biology. I am sorry that I bothered you with my enormous number of questions that you always tried to address patiently. I learned a lot from you, more than I did with anyone else. Also I appreciate that you always gave me all the important information about how to live in Sweden when I just arrived and was totally lost in a new atmosphere.

Diana Cepeda, you are one of the best PhD students I've ever met. Indeed, I learnt many things from you, which you might be aware of but there were also things that you

are not aware of. Hereby, I reveal that you had a great role in a current that eventually modified my way of thinking from a medical doctor's perspective into a biologist's and without even knowing it. I won't tell you how though...

Nimesh Bhaskaran, You are a great man! You have a God-given talent to make everything smoother. Thanks a lot for sharing a complete original Indian dish with me everyday! Thanks for your help, support, valuable comments and finally proofreading. Thanks man!

Mikael Lerner, you were the first person I got to talk to when I came to Danne's lab and you treated me as if you already knew me. You are terribly nice, actually you may consider what I advised Olle in terms of the state of being nice. You helped me greatly to figure things out, but you never revealed how you keep your hair that straight and sticky. Also, I have to confess that I always feel jealous when you talk; it feels like you are reading your sentences from a textbook or an article. Lastly, we need to play the second round of our backgammon tournament. The first one played 5 years ago!

Charis NG, you are great at recipes, no matter if it is viral transformation or baking Pandan cake. I always loved your cakes and as you know, these days, after Salah's statement in his thesis, saying this loudly is not a shame anymore. I love Chris's cakes; I love "cakes" people...

Josefin Lundgren, I could never believe that there might be a living creature so lovely, smart and tough at the same time. You proved that everything is possible. Thanks for establishing the "Dream Team" with me and indeed you did great in miR-27a project. Nice job, nice moments! Finally thanks for all the moments that I seriously and dedicatedly spoke Swedish and you kindly answered in English.

Our other past and present lab members including **Azadeh Arabi**, for teaching me immunofluorescence staining and further support, **Angelina Jahn**, thanks for all the assistance during miR-27a project and lovely cakes, **Natalie von der Lehr**, **Elin Sjöberg** and **Karim**.

All other past and present members of Danne's group;

Martin Corcoran, it was a great pleasure to have you around; you are definitely that kind of a person that makes life more endurable. You are a great scientist and I indeed admire your great bioinformatics skills as well as the number of the primer pairs that you have in those three freezers.

Katja Pokrovskaja, you are immensely kind with a heart made of pure gold! You are a person that any lab must have one of; otherwise it would become a big mess.

Lotte, thank you for being super duper nice, smiling all the time and all the technical assistance during these years, **Linn and Marianne**, you are certainly the most adorable living female scientists, Marianne! I think so despite you didn't let me finish my lecture in CCK kick off, **Farhad** you are a nice friend, thanks indeed for accepting to come to my defense, thanks for all lunch chats and thanks for all pleasant discussions about Persian poem and literature, **Aris** and **Pedram** for being so nice friends and particularly for all the help and supports during FACS optimization, **Masako**, Japan's earthquake/tsunami was so sad but I wish you a happy future and good luck with your defense as well, **Eva B** and **Edward**.

Stefan Einhorn, I would like to convey my regards to you, most likely my scientific career endpoint will resemble yours. I think that it is inevitable fate of scientists who are in love with both science and philosophy.

All the past and present members of the third floor, especially: **Markus**, I never figured out how you can be smiling everyday and also for chats in Swedish, **Jacob**, we never managed to bike to CCK, **Mahdi**, you are a component of an amazing triad, You, Salah and Nimesh. I never laughed that much I did in CCK party 2009, it was not less during our lunch times though, **Arne Östman**, most handsome professor ever seen, **Reiner**, **Katarina**, **Marcela**, **Tao**, **Karin Aase**, **Mira**, **Elisabeth**, **Åsa**, **Christina**, **Mimmi**, **Lars Holmgren**, **Tanya**, **Malihe**, **Jeroen**, **Maja** and **Martin**.

All the other great people at CCK, in particular:

Salah, Sorry buddy, but insulting me for being in love with “cake” is not such a big mystery anymore. You could point out other things... , **Anna V** for great OPUSs, **Erik** even though a short time, still a lot of joys and nice chats during your stay here, **Amir**, thank you for all planning and travel information during these years, I wish you all the best with your little one and also with your defense, **Elham**, **Parviz**, **Mohammad**, **Ali**, **Kambiz**, **Ruby**, **Rona**, **Tomadher**, **Pär**, **Pádraig**, **Wessen**, **Bertha**, **Klas Wiman**, **Kristina**, **Eva M**, **Fredrik**, **Anki**, **Andrea**, **Karin**, **Anna DG**, **Stig Linder**, **Maria B**, **Maria H**, **Linn** and **Margaretha** , I can not imagine the 4th floor without you two. I would like to express my gratitude to all people at CCK that make everything up and running:

Sören Lindén, you are one of the nicest person I have ever seen, apart from your great intelligence to solve all kinds of problems, **Eva-Lena Toikka**, **Ann-Gitt Mattsson**, **Elisabeth Djuph**, **Elle Tisäter**, **Emily Bydén**, **Juan Castro** and **Barbro Larsson**. **Tina Dalianis**, the chairman of the department during my PhD, for making CCK such a creative and friendly research environment.

All the collaborators that made the projects possible and so much easier:

Mohsen Karimi, **Aris pantechoracis**, **Per Sangfelt**, **Helena Karlström**, **Galina Selivanova**, **Charles Spruck**, **Steve Reed**, **Martin Widschwendter**, **Jonas Bergh**, **Linda Lindström**, **Johanna Smed**, and **Omid Beiki**.

All the collaborators and friends in our new place, CMB:

Tersa and Xavier, the most lovely scientist couple I’ve ever met, thank you indeed for your great help and assistance during FACS optimization, **Ayeshe**, it’s great to have a colleague who is native in both English and Swedish, Obviously, thanks a lot for your great help with proofreading of this part and also helping me in my Swedish homeworks! You are also unique as a person with Persian origin who doesn’t know even one word in Persian!, **Matti**, for your sense of humor and being nice, **Hamid Darban**, **Omid Faridani**, **Siamak Akbari**, **Raju**, **Nanaho**, **Ales**, **Piergiorgio** and **Örjan Wrange lab**, **Camilla Sjögren**, **Lena Stöm**, **Zdravko**, **Irrene** and finally **Christer Höög**, the chairman of the department.

Professor Per Hellström, you were the one who brought me to Sweden, I would like to express all my gratitude, what you did was more than a favor, you changed my life and helped my dreams come true. Shirin and I never forgot your hospitality when we arrived to Sweden and since then.

Professor Zali MR, I need to thank you for providing me the possibility to collaborate with KI and all your help and support.

I offer my sincere apology to all those wonderful people that I might have missed to mention but I will always be indebted to you for helping me to finish this job.

My friends from outside the lab: the three musketeers,

Dr. Shahab Fatemi, you have been my best friend for 23 years. I appreciate all those scientific/philosophical chats in high school that initiated my appetite to resolve mysteries. I am incredibly indebted to you.

Dr. Shahriar Anvari, you were my first roommate in my entire life and one of three best friends during our medical studies. We spent days and nights together studying all those heavy medical books and still we got the lowest grades.

Dr. Arash Babapour, for all the time that we spent in our small dorm with Shahriar, we laughed at small things just to forget the hardship of being so far from our families. Finally, I have never met such an intelligent person who prepares the least and gains the highest grades.

Lastly my family members:

My grandmas and grandpas, **Behjat, Batool, Abbas** and **Baba Zandian**, for all the love that you gave me when you were still alive.

My father and mother in law, **Ebrahim Zabihi** and **Manijeh Kamali** for being extremely nice and understanding and for giving me an angel to share my life with.

Dr. Nooshin, congratulations again for your graduation, you did great, no one could put as much force as you did, **Vahid**, my dear brother in law, you have a golden heart and that makes you to buy presents for the whole family each new year! Wish you all the best in your shiny future.

My mother, **Farah**, you were the first one in so many things in my life, the first one who gave me life, the first one who loved me, the first one who fed me, the first who taught me, the first one who everything. Thank you from the bottom of my heart maman!

My father, **Mohammad**, you are my legendary hero. You took care of me, most of the time invisibly, and always encouraged me and made me not forget to follow my scientific dreams. Thank you for everything!

My dearest brother and music collaborator, **Sina**, you are more than nice, I wish you all the best in your future life, my lovely sister **Sheida**, thanks for always being my main driving force to proceed. You are passionate and wise at the same time, which makes you stronger to go ahead. Guys!, I offer my apologies if I have not been the best brother always. I left home when you were small kids and did not have a chance to be around a lot. Thank you for everything!

My dear uncle, **Dr. Ali Akhoondi**, you were the person who inspired me to become a doctor. I used to mimic what you did in your office and my favorite game during my childhood was treating my imaginary patients. I admire your great soul.

Atrin, my dear smart and naughty son. I am sorry for making you sit still during these years (unsuccessfully) especially these days while I am writing my thesis. I am sure you feel by all means that having father defending his PhD thesis is not fun at all, right? I promise to make it up to you, Jag lovar...

Shirin, if there are angels on earth you are one of a kind! I am deeply grateful that you never complained during these tough years and tolerated me when I was shockingly annoying. When my experiments failed you brought me calm and relaxation with your heavenly love – a pillar to lean on. I will never forget all the moments you encouraged my ambitions, which made me sure I was stepping in the right direction. I have been incredibly fortunate to share my life with you.

You're my everlasting love.

6 REFERENCES

1. Sakorafas, G.H. and M. Safioleas, *Breast cancer surgery: an historical narrative. Part I. From prehistoric times to Renaissance*. Eur J Cancer Care (Engl), 2009. **18**(6): p. 530-44.
2. Hanahan, D. and R.A. Weinberg, *The hallmarks of cancer*. Cell, 2000. **100**(1): p. 57-70.
3. Hanahan, D. and R.A. Weinberg, *Hallmarks of cancer: the next generation*. Cell, 2011. **144**(5): p. 646-74.
4. Dranitsaris, G., et al., *Advances in cancer therapeutics and patient access to new drugs*. Pharmacoeconomics, 2011. **29**(3): p. 213-24.
5. ; Available from:
http://www.who.int.proxy.kib.ki.se/nmh/publications/fact_sheet_cancers_en.pdf.
6. Ghosh, A. and M. Bansal, *A glossary of DNA structures from A to Z*. Acta Crystallogr D Biol Crystallogr, 2003. **59**(Pt 4): p. 620-6.
7. Croce, C.M., *Oncogenes and cancer*. N Engl J Med, 2008. **358**(5): p. 502-11.
8. Eilers, M. and R.N. Eisenman, *Myc's broad reach*. Genes Dev, 2008. **22**(20): p. 2755-66.
9. Peterson, C.L. and J.L. Workman, *Promoter targeting and chromatin remodeling by the SWI/SNF complex*. Curr Opin Genet Dev, 2000. **10**(2): p. 187-92.
10. Jenuwein, T. and C.D. Allis, *Translating the histone code*. Science, 2001. **293**(5532): p. 1074-80.
11. Nakamura, T., et al., *ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation*. Mol Cell, 2002. **10**(5): p. 1119-28.
12. Heldin, C.H. and B. Westermark, *Mechanism of action and in vivo role of platelet-derived growth factor*. Physiol Rev, 1999. **79**(4): p. 1283-316.
13. Heldin, C.H., *Dimerization of cell surface receptors in signal transduction*. Cell, 1995. **80**(2): p. 213-23.
14. Pawson, T. and N. Warner, *Oncogenic re-wiring of cellular signaling pathways*. Oncogene, 2007. **26**(9): p. 1268-75.
15. Tsujimoto, Y., et al., *Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation*. Science, 1984. **224**(4656): p. 1403-6.
16. Tsujimoto, Y., et al., *Involvement of the bcl-2 gene in human follicular lymphoma*. Science, 1985. **228**(4706): p. 1440-3.
17. Konopka, J.B., et al., *Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration*. Proc Natl Acad Sci U S A, 1985. **82**(6): p. 1810-4.
18. Tsujimoto, Y., et al., *The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining*. Science, 1985. **229**(4720): p. 1390-3.
19. Coppola, D., *Mechanisms of Oncogenesis: An Update on Tumorigenesis 2010*.
20. Bishop, J.M., *Molecular themes in oncogenesis*. Cell, 1991. **64**(2): p. 235-48.
21. Negrini, M., et al., *MicroRNAs in human cancer: from research to therapy*. J Cell Sci, 2007. **120**(Pt 11): p. 1833-40.
22. Esquela-Kerscher, A. and F.J. Slack, *Oncomirs - microRNAs with a role in cancer*. Nat Rev Cancer, 2006. **6**(4): p. 259-69.
23. Weinberg, R.A., *The biology of cancer*. 2007.
24. Knudson, A.G., Jr., *Mutation and cancer: statistical study of retinoblastoma*. Proc Natl Acad Sci U S A, 1971. **68**(4): p. 820-3.
25. Berger, A.H. and P.P. Pandolfi, *Haplo-insufficiency: a driving force in cancer*. J Pathol, 2011. **223**(2): p. 137-46.
26. Sherr, C.J., *Principles of tumor suppression*. Cell, 2004. **116**(2): p. 235-46.
27. Markowitz, S., *DNA repair defects inactivate tumor suppressor genes and induce hereditary and sporadic colon cancers*. J Clin Oncol, 2000. **18**(21 Suppl): p. 75S-80S.

28. Wouters, M.D., et al., *MicroRNAs, the DNA Damage Response and Cancer*. Mutat Res, 2011.
29. Stratton, M.R., *Exploring the genomes of cancer cells: progress and promise*. Science, 2011. **331**(6024): p. 1553-8.
30. Lahtz, C. and G.P. Pfeifer, *Epigenetic changes of DNA repair genes in cancer*. J Mol Cell Biol, 2011. **3**(1): p. 51-8.
31. Yoshida, B.A., et al., *Metastasis-suppressor genes: a review and perspective on an emerging field*. J Natl Cancer Inst, 2000. **92**(21): p. 1717-30.
32. Hirohashi, S. and Y. Kanai, *Cell adhesion system and human cancer morphogenesis*. Cancer Sci, 2003. **94**(7): p. 575-81.
33. Lundberg, A.S., et al., *Genes involved in senescence and immortalization*. Curr Opin Cell Biol, 2000. **12**(6): p. 705-9.
34. Lu, Z. and R.C. Bast, Jr., *Tumor suppressor genes*. Cancer Treat Res, 2009. **149**: p. 109-29.
35. Campbell, I., W. Qiu, and I. Haviv, *Genetic changes in tumour microenvironments*. J Pathol, 2011. **223**(4): p. 450-8.
36. Bedford, L., et al., *Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets*. Nat Rev Drug Discov, 2011. **10**(1): p. 29-46.
37. Chen, D. and Q.P. Dou, *The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention*. Curr Protein Pept Sci, 2010. **11**(6): p. 459-70.
38. Schoenheimer, R., *The Dynamic State of Body Constituents* 1942: (Cambridge, Massachusetts, Harvard University Press).
39. Herczenik, E. and M.F. Gebbink, *Molecular and cellular aspects of protein misfolding and disease*. FASEB J, 2008. **22**(7): p. 2115-33.
40. Ciechanover, A., *Proteolysis: from the lysosome to ubiquitin and the proteasome*. Nat Rev Mol Cell Biol, 2005. **6**(1): p. 79-87.
41. Giles, J., *Chemistry Nobel for trio who revealed molecular death-tag*. Nature, 2004. **431**(7010): p. 729.
42. Hershko, A., *Ubiquitin: roles in protein modification and breakdown*. Cell, 1983. **34**(1): p. 11-2.
43. Pickart, C.M. and R.E. Cohen, *Proteasomes and their kin: proteases in the machine age*. Nat Rev Mol Cell Biol, 2004. **5**(3): p. 177-87.
44. Hicke, L. and R. Dunn, *Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins*. Annu Rev Cell Dev Biol, 2003. **19**: p. 141-72.
45. Ulrich, H.D., *Degradation or maintenance: actions of the ubiquitin system on eukaryotic chromatin*. Eukaryot Cell, 2002. **1**(1): p. 1-10.
46. Hicke, L., H.L. Schubert, and C.P. Hill, *Ubiquitin-binding domains*. Nat Rev Mol Cell Biol, 2005. **6**(8): p. 610-21.
47. Hicke, L., *Protein regulation by monoubiquitin*. Nat Rev Mol Cell Biol, 2001. **2**(3): p. 195-201.
48. Reed, S.I., *Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover*. Nat Rev Mol Cell Biol, 2003. **4**(11): p. 855-64.
49. Pickart, C.M., *Mechanisms underlying ubiquitination*. Annu Rev Biochem, 2001. **70**: p. 503-33.
50. Lorick, K.L., et al., *RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination*. Proc Natl Acad Sci U S A, 1999. **96**(20): p. 11364-9.
51. Varshavsky, A., *Naming a targeting signal*. Cell, 1991. **64**(1): p. 13-5.
52. Bai, C., et al., *SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box*. Cell, 1996. **86**(2): p. 263-74.
53. Patton, E.E., A.R. Willems, and M. Tyers, *Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis*. Trends Genet, 1998. **14**(6): p. 236-43.
54. Jin, J., et al., *Systematic analysis and nomenclature of mammalian F-box proteins*. Genes Dev, 2004. **18**(21): p. 2573-80.
55. Cardozo, T. and M. Pagano, *The SCF ubiquitin ligase: insights into a molecular machine*. Nat Rev Mol Cell Biol, 2004. **5**(9): p. 739-51.
56. Nakayama, K.I. and K. Nakayama, *Ubiquitin ligases: cell-cycle control and cancer*. Nat Rev Cancer, 2006. **6**(5): p. 369-81.

57. Bornstein, G., et al., *Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase*. J Biol Chem, 2003. **278**(28): p. 25752-7.
58. Welcker, M. and B.E. Clurman, *FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation*. Nat Rev Cancer, 2008. **8**(2): p. 83-93.
59. Feldman, R.M., et al., *A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p*. Cell, 1997. **91**(2): p. 221-30.
60. Henchoz, S., et al., *Phosphorylation- and ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor Far1p in budding yeast*. Genes Dev, 1997. **11**(22): p. 3046-60.
61. Tan, Y., O. Sangfelt, and C. Spruck, *The Fbxw7/hCdc4 tumor suppressor in human cancer*. Cancer Lett, 2008. **271**(1): p. 1-12.
62. Matsumoto, A., I. Onoyama, and K.I. Nakayama, *Expression of mouse Fbxw7 isoforms is regulated in a cell cycle- or p53-dependent manner*. Biochem Biophys Res Commun, 2006. **350**(1): p. 114-9.
63. Spruck, C.H., et al., *hCDC4 gene mutations in endometrial cancer*. Cancer Res, 2002. **62**(16): p. 4535-9.
64. Smith, T.F., et al., *The WD repeat: a common architecture for diverse functions*. Trends Biochem Sci, 1999. **24**(5): p. 181-5.
65. Welcker, M. and B.E. Clurman, *FBW7/hCDC4 dimerization regulates its substrate interactions*. Cell Div, 2007. **2**: p. 7.
66. Tang, X., et al., *Suprafacial orientation of the SCFCdc4 dimer accommodates multiple geometries for substrate ubiquitination*. Cell, 2007. **129**(6): p. 1165-76.
67. Zhang, W. and D.M. Koepp, *FBW7 isoform interaction contributes to cyclin E proteolysis*. Mol Cancer Res, 2006. **4**(12): p. 935-43.
68. Welcker, M., et al., *A nucleolar isoform of the FBW7 ubiquitin ligase regulates c-Myc and cell size*. Curr Biol, 2004. **14**(20): p. 1852-7.
69. Koepp, D.M., et al., *Phosphorylation-dependent ubiquitination of cyclin E by the SCFFBW7 ubiquitin ligase*. Science, 2001. **294**(5540): p. 173-7.
70. Kimura, T., et al., *hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53*. Cancer Sci, 2003. **94**(5): p. 431-6.
71. Welcker, M., et al., *Nucleolar targeting of the FBW7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3*. Mol Cell Biol, 2011. **31**(6): p. 1214-24.
72. Matsumoto, A., et al., *Fbxw7beta resides in the endoplasmic reticulum membrane and protects cells from oxidative stress*. Cancer Sci, 2011. **102**(4): p. 749-55.
73. Ye, X., et al., *Recognition of phosphodegron motifs in human cyclin E by the SCF(FBW7) ubiquitin ligase*. J Biol Chem, 2004. **279**(48): p. 50110-9.
74. Nash, P., et al., *Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication*. Nature, 2001. **414**(6863): p. 514-21.
75. Orlicky, S., et al., *Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase*. Cell, 2003. **112**(2): p. 243-56.
76. Hao, B., et al., *Structure of a FBW7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases*. Mol Cell, 2007. **26**(1): p. 131-43.
77. Ekholm-Reed, S., et al., *Deregulation of cyclin E in human cells interferes with prereplication complex assembly*. J Cell Biol, 2004. **165**(6): p. 789-800.
78. Spruck, C.H., K.A. Won, and S.I. Reed, *Deregulated cyclin E induces chromosome instability*. Nature, 1999. **401**(6750): p. 297-300.
79. Nielsen, N.H., et al., *Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status*. Br J Cancer, 1996. **74**(6): p. 874-80.
80. Keyomarsi, K., et al., *Cyclin E and survival in patients with breast cancer*. N Engl J Med, 2002. **347**(20): p. 1566-75.
81. Willmarth, N.E., D.G. Albertson, and S.P. Ethier, *Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells*. Breast Cancer Res, 2004. **6**(5): p. R531-9.

82. Bortner, D.M. and M.P. Rosenberg, *Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E*. Mol Cell Biol, 1997. **17**(1): p. 453-9.
83. Haas, K., et al., *Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4*. Oncogene, 1997. **15**(21): p. 2615-23.
84. Dealy, M.J., et al., *Loss of Cull1 results in early embryonic lethality and dysregulation of cyclin E*. Nat Genet, 1999. **23**(2): p. 245-8.
85. Wang, Y., et al., *Deletion of the Cull1 gene in mice causes arrest in early embryogenesis and accumulation of cyclin E*. Curr Biol, 1999. **9**(20): p. 1191-4.
86. Moberg, K.H., et al., *Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines*. Nature, 2001. **413**(6853): p. 311-6.
87. Strohmaier, H., et al., *Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line*. Nature, 2001. **413**(6853): p. 316-22.
88. Clurman, B.E., et al., *Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation*. Genes Dev, 1996. **10**(16): p. 1979-90.
89. Welcker, M., et al., *Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation*. Mol Cell, 2003. **12**(2): p. 381-92.
90. Won, K.A. and S.I. Reed, *Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E*. EMBO J, 1996. **15**(16): p. 4182-93.
91. van Drogen, F., et al., *Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms*. Mol Cell, 2006. **23**(1): p. 37-48.
92. Sangfelt, O., et al., *Both SCF(Cdc4alpha) and SCF(Cdc4gamma) are required for cyclin E turnover in cell lines that do not overexpress cyclin E*. Cell Cycle, 2008. **7**(8): p. 1075-82.
93. Bray, S.J., *Notch signalling: a simple pathway becomes complex*. Nat Rev Mol Cell Biol, 2006. **7**(9): p. 678-89.
94. Wu, L., et al., *MAMLI, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors*. Nat Genet, 2000. **26**(4): p. 484-9.
95. Ellisen, L.W., et al., *TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms*. Cell, 1991. **66**(4): p. 649-61.
96. Guo, S., M. Liu, and R.R. Gonzalez-Perez, *Role of Notch and its oncogenic signaling crosstalk in breast cancer*. Biochim Biophys Acta, 2011. **1815**(2): p. 197-213.
97. Allenspach, E.J., et al., *Notch signaling in cancer*. Cancer Biol Ther, 2002. **1**(5): p. 466-76.
98. Sundaram, M. and I. Greenwald, *Suppressors of a lin-12 hypomorph define genes that interact with both lin-12 and glp-1 in Caenorhabditis elegans*. Genetics, 1993. **135**(3): p. 765-83.
99. Hubbard, E.J., et al., *sel-10, a negative regulator of lin-12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins*. Genes Dev, 1997. **11**(23): p. 3182-93.
100. Gupta-Rossi, N., et al., *Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor*. J Biol Chem, 2001. **276**(37): p. 34371-8.
101. Itoh, M., et al., *Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta*. Dev Cell, 2003. **4**(1): p. 67-82.
102. Qiu, L., et al., *Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase*. J Biol Chem, 2000. **275**(46): p. 35734-7.
103. Tsunematsu, R., et al., *Mouse FBW7/Sel-10/Cdc4 is required for notch degradation during vascular development*. J Biol Chem, 2004. **279**(10): p. 9417-23.
104. Weng, A.P., et al., *Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia*. Science, 2004. **306**(5694): p. 269-71.
105. Thompson, B.J., et al., *The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia*. J Exp Med, 2007. **204**(8): p. 1825-35.
106. Tetzlaff, M.T., et al., *Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the FBW7 F-box protein*. Proc Natl Acad Sci U S A, 2004. **101**(10): p. 3338-45.

107. Hartl, M., et al., *Stem cell-specific activation of an ancestral myc protooncogene with conserved basic functions in the early metazoan Hydra*. Proc Natl Acad Sci U S A, 2010. **107**(9): p. 4051-6.
108. Amati, B., et al., *Oncogenic activity of the c-Myc protein requires dimerization with Max*. Cell, 1993. **72**(2): p. 233-45.
109. Cole, M.D., *The myc oncogene: its role in transformation and differentiation*. Annu Rev Genet, 1986. **20**: p. 361-84.
110. Coppola, J.A. and M.D. Cole, *Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment*. Nature, 1986. **320**(6064): p. 760-3.
111. Davis, A.C., et al., *A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice*. Genes Dev, 1993. **7**(4): p. 671-82.
112. Hydbring, P., et al., *Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation*. Proc Natl Acad Sci U S A, 2010. **107**(1): p. 58-63.
113. Adhikary, S. and M. Eilers, *Transcriptional regulation and transformation by Myc proteins*. Nat Rev Mol Cell Biol, 2005. **6**(8): p. 635-45.
114. Dalla-Favera, R., et al., *Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells*. Proc Natl Acad Sci U S A, 1982. **79**(24): p. 7824-7.
115. Dalla-Favera, R., et al., *Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas*. Science, 1983. **219**(4587): p. 963-7.
116. Pelengaris, S., M. Khan, and G. Evan, *c-MYC: more than just a matter of life and death*. Nat Rev Cancer, 2002. **2**(10): p. 764-76.
117. Welcker, M., et al., *The FBW7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation*. Proc Natl Acad Sci U S A, 2004. **101**(24): p. 9085-90.
118. Yeh, E., et al., *A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells*. Nat Cell Biol, 2004. **6**(4): p. 308-18.
119. Yada, M., et al., *Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein FBW7*. EMBO J, 2004. **23**(10): p. 2116-25.
120. Sears, R., et al., *Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability*. Genes Dev, 2000. **14**(19): p. 2501-14.
121. Akhoondi, S., et al., *Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer*. Breast Cancer Res, 2010. **12**(6): p. R105.
122. Mao, J.H., et al., *Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene*. Nature, 2004. **432**(7018): p. 775-9.
123. Balamurugan, K., et al., *The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis*. EMBO J, 2010. **29**(24): p. 4106-17.
124. Jaenisch, R. and A. Bird, *Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals*. Nat Genet, 2003. **33** Suppl: p. 245-54.
125. Filipowicz, W., S.N. Bhattacharyya, and N. Sonenberg, *Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?* Nat Rev Genet, 2008. **9**(2): p. 102-14.
126. Fire, A., et al., *Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans*. Nature, 1998. **391**(6669): p. 806-11.
127. Cai, X., C.H. Hagedorn, and B.R. Cullen, *Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs*. RNA, 2004. **10**(12): p. 1957-66.
128. Lee, Y., et al., *MicroRNA genes are transcribed by RNA polymerase II*. EMBO J, 2004. **23**(20): p. 4051-60.
129. Yi, R., et al., *Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs*. Genes Dev, 2003. **17**(24): p. 3011-6.
130. Gregory, R.I., et al., *Human RISC couples microRNA biogenesis and posttranscriptional gene silencing*. Cell, 2005. **123**(4): p. 631-40.

131. Du, T. and P.D. Zamore, *microPrimer: the biogenesis and function of microRNA*. Development, 2005. **132**(21): p. 4645-52.
132. Martinez, J. and T. Tuschl, *RISC is a 5' phosphomonoester-producing RNA endonuclease*. Genes Dev, 2004. **18**(9): p. 975-80.
133. Osada, H. and T. Takahashi, *MicroRNAs in biological processes and carcinogenesis*. Carcinogenesis, 2007. **28**(1): p. 2-12.
134. Shomron, N., *MicroRNAs and pharmacogenomics*. Pharmacogenomics, 2010. **11**(5): p. 629-32.
135. Brodersen, P. and O. Voinnet, *Revisiting the principles of microRNA target recognition and mode of action*. Nat Rev Mol Cell Biol, 2009. **10**(2): p. 141-8.
136. Ghildiyal, M. and P.D. Zamore, *Small silencing RNAs: an expanding universe*. Nat Rev Genet, 2009. **10**(2): p. 94-108.
137. Agami, R., *microRNAs, RNA binding proteins and cancer*. Eur J Clin Invest, 2010. **40**(4): p. 370-4.
138. Xu, Y., et al., *MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7*. J Biol Chem, 2010. **285**(45): p. 34439-46.
139. Kedde, M., et al., *A Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibility*. Nat Cell Biol, 2010. **12**(10): p. 1014-20.
140. van Kerkhof, P., J. Putters, and G.J. Strous, *The ubiquitin ligase SCF(betaTrCP) regulates the degradation of the growth hormone receptor*. J Biol Chem, 2007. **282**(28): p. 20475-83.
141. Merlet, J., et al., *Regulation of cullin-RING E3 ubiquitin-ligases by neddylation and dimerization*. Cell Mol Life Sci, 2009. **66**(11-12): p. 1924-38.
142. Wu, J.T., Y.R. Chan, and C.T. Chien, *Protection of cullin-RING E3 ligases by CSN-UBP12*. Trends Cell Biol, 2006. **16**(7): p. 362-9.
143. Oberg, C., et al., *The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog*. J Biol Chem, 2001. **276**(38): p. 35847-53.
144. Pashkova, N., et al., *WD40 repeat propellers define a ubiquitin-binding domain that regulates turnover of F box proteins*. Mol Cell, 2010. **40**(3): p. 433-43.
145. Matsuoka, S., et al., *ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage*. Science, 2007. **316**(5828): p. 1160-6.
146. Durgan, J. and P.J. Parker, *Regulation of the tumour suppressor FBW7alpha by PKC-dependent phosphorylation and cancer-associated mutations*. Biochem J, 2010. **432**(1): p. 77-87.
147. Suzuki, H., et al., *Homodimer of two F-box proteins betaTrCP1 or betaTrCP2 binds to IkkappaBalpha for signal-dependent ubiquitination*. J Biol Chem, 2000. **275**(4): p. 2877-84.
148. Kominami, K., I. Ochotorena, and T. Toda, *Two F-box/WD-repeat proteins Pop1 and Pop2 form hetero- and homo-complexes together with cullin-1 in the fission yeast SCF (Skp1-Cullin-1-F-box) ubiquitin ligase*. Genes Cells, 1998. **3**(11): p. 721-35.
149. Yeh, E.S., B.O. Lew, and A.R. Means, *The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability*. J Biol Chem, 2006. **281**(1): p. 241-51.
150. Joseph, J.D., et al., *The peptidyl-prolyl isomerase Pin1*. Prog Cell Cycle Res, 2003. **5**: p. 477-87.
151. Namgoong, G.M., et al., *The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer*. J Biol Chem, 2010. **285**(31): p. 23829-41.
152. Pulikkan, J.A., et al., *Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML*. Leukemia, 2010. **24**(5): p. 914-23.
153. Rudrabhatla, P. and H.C. Pant, *Phosphorylation-specific peptidyl-prolyl isomerization of neuronal cytoskeletal proteins by Pin1: implications for therapeutics in neurodegeneration*. J Alzheimers Dis, 2010. **19**(2): p. 389-403.
154. Catanzaro, J. and W.X. Zong, *Pinpointing Pin1 in non-small cell lung carcinoma*. Cancer Biol Ther, 2010. **9**(2): p. 120-1.
155. Xu, G.G. and F.A. Etzkorn, *Pin1 as an anticancer drug target*. Drug News Perspect, 2009. **22**(7): p. 399-407.

156. Popov, N., et al., *The ubiquitin-specific protease USP28 is required for MYC stability*. Nat Cell Biol, 2007. **9**(7): p. 765-74.
157. Popov, N., et al., *FBW7 and Usp28 regulate myc protein stability in response to DNA damage*. Cell Cycle, 2007. **6**(19): p. 2327-31.
158. Bonetti, P., et al., *Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through FBW7 gamma*. J Cell Biol, 2008. **182**(1): p. 19-26.
159. Li, Z., D. Boone, and S.R. Hann, *Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation*. Proc Natl Acad Sci U S A, 2008. **105**(48): p. 18794-9.
160. Kitagawa, K., et al., *GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms*. Cell Div, 2010. **5**: p. 27.
161. Minella, A.C., M. Welcker, and B.E. Clurman, *Ras activity regulates cyclin E degradation by the FBW7 pathway*. Proc Natl Acad Sci U S A, 2005. **102**(27): p. 9649-54.
162. Rajagopalan, H., et al., *Inactivation of hCDC4 can cause chromosomal instability*. Nature, 2004. **428**(6978): p. 77-81.
163. Rajagopalan, H. and C. Lengauer, *hCDC4 and genetic instability in cancer*. Cell Cycle, 2004. **3**(6): p. 693-4.
164. Byrd, K.N., et al., *FBXW7 and DNA copy number instability*. Breast Cancer Res Treat, 2008. **109**(1): p. 47-54.
165. Finkin, S., et al., *FBW7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy*. Oncogene, 2008. **27**(32): p. 4411-21.
166. Calhoun, E.S., et al., *BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets*. Am J Pathol, 2003. **163**(4): p. 1255-60.
167. Kemp, Z., et al., *CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability*. Cancer Res, 2005. **65**(24): p. 11361-6.
168. Akhondi, S., et al., *FBXW7/hCDC4 is a general tumor suppressor in human cancer*. Cancer Res, 2007. **67**(19): p. 9006-12.
169. Malyukova, A., et al., *The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling*. Cancer Res, 2007. **67**(12): p. 5611-6.
170. Kox, C., et al., *The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function*. Leukemia, 2010. **24**(12): p. 2005-13.
171. Park, M.J., et al., *FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma*. Br J Haematol, 2009. **145**(2): p. 198-206.
172. Asnafi, V., et al., *NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study*. Blood, 2009. **113**(17): p. 3918-24.
173. Knuutila, S., et al., *DNA copy number losses in human neoplasms*. Am J Pathol, 1999. **155**(3): p. 683-94.
174. Sterian, A., et al., *Mutational and LOH analyses of the chromosome 4q region in esophageal adenocarcinoma*. Oncology, 2006. **70**(3): p. 168-72.
175. Sancho, R., et al., *F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor*. Gastroenterology, 2010. **139**(3): p. 929-41.
176. Hagedorn, M., et al., *FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients*. Cell Div, 2007. **2**: p. 9.
177. Yokobori, T., et al., *p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases*. Cancer Res, 2009. **69**(9): p. 3788-94.
178. Iwatsuki, M., et al., *Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance*. Int J Cancer, 2010. **126**(8): p. 1828-37.
179. Gu, Z., et al., *Promoter hypermethylation is not the major mechanism for inactivation of the FBXW7 beta-form in human gliomas*. Genes Genet Syst, 2008. **83**(4): p. 347-52.

180. Iqbal, K., et al., *Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine*. Proc Natl Acad Sci U S A, 2011. **108**(9): p. 3642-7.
181. Gu, Z., et al., *The methylation status of FBXW7 beta-form correlates with histological subtype in human thymoma*. Biochem Biophys Res Commun, 2008. **377**(2): p. 685-8.
182. Gottardo, F., et al., *Micro-RNA profiling in kidney and bladder cancers*. Urol Oncol, 2007. **25**(5): p. 387-92.
183. Chiaretti, S., et al., *Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223*. Haematologica, 2010. **95**(7): p. 1114-21.
184. Wang, Q., et al., *Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen*. Oncogene, 2011.
185. Ray, S., M.E. Anderson, and P. Tegtmeyer, *Differential interaction of temperature-sensitive simian virus 40 T antigens with tumor suppressors pRb and p53*. J Virol, 1996. **70**(10): p. 7224-7.
186. DeCaprio, J.A., et al., *SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene*. Cell, 1988. **54**(2): p. 275-83.
187. Welcker, M. and B.E. Clurman, *The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with FBW7/hCdc4*. J Biol Chem, 2005. **280**(9): p. 7654-8.
188. Zheng, Z.M., *Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses*. Int J Biol Sci, 2010. **6**(7): p. 730-55.
189. Isobe, T., et al., *Adenovirus E1A inhibits SCF(FBW7) ubiquitin ligase*. J Biol Chem, 2009. **284**(41): p. 27766-79.
190. Di Fiore, P.P., *Playing both sides: nucleophosmin between tumor suppression and oncogenesis*. J Cell Biol, 2008. **182**(1): p. 7-9.
191. Wang, Z., et al., *Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy*. Nature, 2008. **455**(7217): p. 1205-9.
192. Arbisser, J.L., et al., *Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways*. Proc Natl Acad Sci U S A, 1997. **94**(3): p. 861-6.
193. Nalepa, G., M. Rolfe, and J.W. Harper, *Drug discovery in the ubiquitin-proteasome system*. Nat Rev Drug Discov, 2006. **5**(7): p. 596-613.
194. Richardson, P.G., et al., *A phase 2 study of bortezomib in relapsed, refractory myeloma*. N Engl J Med, 2003. **348**(26): p. 2609-17.
195. Richardson, P.G., et al., *Bortezomib or high-dose dexamethasone for relapsed multiple myeloma*. N Engl J Med, 2005. **352**(24): p. 2487-98.
196. Berenson, J.R., et al., *Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma*. Cancer, 2005. **104**(10): p. 2141-8.
197. Wright, J.J., *Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy*. Clin Cancer Res, 2010. **16**(16): p. 4094-104.
198. Cardoso, F., et al., *Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner*. Mol Cancer Ther, 2006. **5**(12): p. 3042-51.
199. Tsvetkov, L.M., et al., *p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27*. Curr Biol, 1999. **9**(12): p. 661-4.
200. Philipp-Staheli, J., S.R. Payne, and C.J. Kemp, *p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer*. Exp Cell Res, 2001. **264**(1): p. 148-68.
201. Grinkevich, V.V., et al., *Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis*. Cancer Cell, 2009. **15**(5): p. 441-53.
202. Jiang, H., et al., *The combined status of ATM and p53 link tumor development with therapeutic response*. Genes Dev, 2009. **23**(16): p. 1895-909.
203. Bryant, H.E., et al., *Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase*. Nature, 2005. **434**(7035): p. 913-7.
204. Orlicky, S., et al., *An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase*. Nat Biotechnol, 2010. **28**(7): p. 733-7.

205. Bartel, D.P., *MicroRNAs: genomics, biogenesis, mechanism, and function*. Cell, 2004. **116**(2): p. 281-97.